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Progressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive 
cholestatic diseases that affects especially new-borns and children. These disorders 
unavoidably progressive to liver cirrhosis and portal hypertension, requiring liver 
transplantation. In most severe cases the progression to liver failure may occur in the first 
decades of life. PFIC is considered a rare disease with an estimated incidence of 1/50,000 to 
1/100,000 births but it is hard to establish because of difficulties in diagnosis.  
The disease has been classified into five types (PFIC1-5) based on the genetic defect involved 
in bile transport. The three first described PFIC-associated genes are ATP8B1 (PFIC1), 
ABCB11 (PFIC2) and ABCB4 (PFIC3) encoding FIC1 (a P-type ATPase), BSEP and MDR3 
(ABC transporters) proteins, respectively. These proteins are all located in the canalicular 
membrane of hepatocytes and mediate bile production. Homozygous or compound 
heterozygous mutations in those tree genes cause severe forms of cholestasis with an early 
onset, requiring liver transplantation in childhood. Heterozygous variants have also been 
linked to milder cholestatic phenotypes or non-progressive forms. After, mutations in TJP2, 
coding for tight junction protein 2, were linked to PFIC4. Recently, mutations in NR1H4 
gene, coding the Farnesoid X receptor (FXR), and mutations in MYO5B, coding Myosin VB 
protein, have been associated to PFIC5 and to PFIC-like form without microvillus inclusion 
disease, respectively. Other genes are suspected to be involved in the disease. 
The aim of the project is to develop and validate a broad, reliable, rapid and cost-saving 
NGS genetic test for PFIC patients. 96 patients were sequenced with the four-gene panel 
and 80 patients were sequenced with the latest discovered genes (fifteen-gene panel). 
A total of 184 different variations has been identified in all patients in the two panels: 18 
pathogenic, 46 of uncertain significance, 44 likely benign and 76 benign. P/LP mutations 
were found in 12% of patients. Many patients had multiple variants in all genes. Patients in 
our cohort have from 7 to 35 variants each and we statistically demonstrate that also some 
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SNPs can be significantly involved in biochemical parameters and in phenotypic features 
that could accelerate the progression to liver failure. The high SNPs prevalence let us to 
hypothesize a synergistic haplotype effect in determining different cholestasis phenotypes 
and overlapping features.  
After all, our detection rate is comparable to the literature and to other studies proposing 
multi-gene panels. This innovative test may be useful for the molecular diagnostics of PFIC 
and a better characterization and understanding of the linking between molecular defects 
and different subtypes of the disease. NGS method guarantees to reach quickly medical 
reports for all patients and their related, so should have great consequences on disease 




SECTION I: INTRODUCTION  
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1.1 Bile: synthesis, transport and regulation  
Bile or gall is a dark green to yellowish brown fluid, produced by the liver of most 
vertebrates, that aids the digestion of lipids in the small intestine. In humans, bile is 
produced continuously by the liver, stored and concentrated in the gallbladder. After 
eating, stored bile is discharged into the duodenum. The composition of hepatic bile is 97% 
water, 0.7% bile salts, 0.2% bilirubin, 0.51% fats (cholesterol, fatty acids and lecithin) and 
inorganic salts. About 400 to 800 ml of bile is produced per day in adult human beings. 
It is a physiological key function that leads the endo- and xenobiotics excretory way, 
enabling digestion and lipid absorption from the intestinal lumen. Bile secretion happens 
because of the osmotic filtration process: in this mechanism the secretion of osmotically 
active elements from hepatocytes to canalicular space establish water flow through 
intercellular tight junctions that are impermeable to bigger size molecules 1. Among these 
solutes secreted in the duct, there are bile acids (BA), glutathione and various organic 
anions, in addition to bicarbonate, proteins, organic cations and lipids. Bile acids are the 
main solutes in bile and are regarded as the dominant osmotic driving force in its 
production 2. Canalicular excretion of bile acids involves three phases: first, a highly efficient 
uptake from portal blood in the hepatic sinusoid; second, intracellular transport in the 
hepatocyte that usually can occur with the aid of chemical modifications (such as 
conjugation with glucuronic acid or aminoacids, hydroxylation, sulfation, etc.) and finally, 
excretion to biliary canaliculi 3. After secretion into the intestinal lumen, bile acids are 
efficiently reabsorbed (95% of secreted BA) by the liver via the portal vein for reuptake at 
the sinusoidal pole of hepatocytes. In the last decades, the elucidation of the molecular 
features of proteins involved in hepatocyte transport as well as of the biology of biliary 
epithelia and the role of several nuclear receptors in regulating the expression of key 
transporters and enzymes, have provided a more detailed knowledge of the regulation of 
hepatobiliary transport in physiological and pathological conditions such as cholestasis 4. 
Moreover, due to the importance of bile acids in determining cell injury and death in both 
hepatocytes and cholangiocytes and its possible role as trigger in the inflammatory response 
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in cholestatic disease, many studies are focusing on new BA-based therapeutic strategies 
with promising results 5.  
The vectorial transport of bile acids by hepatocytes involves several transport proteins and 
enzymes (figure 1), including the sinusoidal transporters Sodium Taurocholate Co-
transporting Polypeptide (NTCP/SLC10A1), members of the Organic Anion Transporting 
Polypeptides (OATPs/SLCO) family and conjugation enzymes. ATP-dependent efflux 
pump BSEP (Bile Salt Export Pump) is responsible for excretion of monovalent bile acids 
and conjugate export pump MRP2 (Multidrug Resistance-Associated Protein 2) for 
excretion of bilirubin and divalent bile acids (on the canalicular membrane). The multidrug 
export pump MDR1 assists in the excretion of cationic drugs 6. The phospholipid export 
pump MDR3 “flops” phosphatidylcholine from the inner to the outer membrane leaflets, 
which forms mixed micelles together with bile acids and cholesterol. Other bile acids export 
pumps, MRP3, MRP4 and organic solute transporter (OSTa/b) are present at the basolateral 
membrane and function as back-up pumps for alternative sinusoidal bile acid export. The 
cystic fibrosis transmembrane conductance regulator (CFTR) drives bicarbonate excretion 
and, in the liver, it is expressed only in cholangiocytes. The biliary epithelium also reabsorbs 
bile acids via an apical Na+-dependent bile-salt transporter ASBT and the basolateral 





Figure 1. Overview of bile acid transport system. See details in the text. NTCP: sodium taurocholate co-transporting 
polypeptide; FIC1: Familial intrahepatic cholestasis 1; AE2: Solute Carrier Family 4 (Anion Exchanger), Member 2; OATPs: 
Organic anion transporters; BSEP: Bile-salt export pump; CFTR: Cystic fibrosis transmembrane conductance regulator; 
OST: Organic solute transporter; ASBT: Apical sodium-dependent bile-salt transporter. Samant H, Manatsathit W, Dies D, 
et al. World J Clin Cases 2019. 
 
These proteins have a central role managing a rapid transition of bile acids from blood to 
bile and maintaining a low intracellular bile acids concentration. This is crucial to maintain 
hepatocyte integrity as bile acids are both signalling and detergent molecules that, at higher 
concentration (≥ 50 μM/L), may cause apoptosis, activate proinflammatory genes, and 
eventually induce cellular necrosis 7. This cytotoxicity of bile acids leads to liver damage in 
cholestatic conditions: bile secretion is impaired, bile acids accumulate inside hepatocytes 
and, in the case of cholangiopathies, leak into the surrounding tissue due to injury of bile 
ducts. When this happens, the cholestatic setting alterations in the expression of 
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hepatobiliary transporters could represent a compensatory response aiming to limit the 
accumulation of potentially toxic biliary constituents. These adaptive responses are 
mediated by the activation of several nuclear receptors such as Farnesoid X Receptor (FXR), 
Pregnane X Receptor (PXR), Constitutive Active Response (CAR) and Small Heterodimer 
Partner (SHP) as well as by entero-hormones such as FGF-19 8. FXR is the major bile acids 
receptor and influences a myriad of pathways both in hepatocytes and in other resident cells 
such as Kupffer, endothelial and hepatic stellate cells. In hepatocytes, upon upregulation of 
SHP, FXR mediates a downregulation of NTCP and of a key enzyme in bile acid synthesis, 
CYP7A1 (Cytochrome P450 7A1). FXR also directly up-regulates BSEP, thus promoting bile 
acid excretion 9. Lastly, alternative excretory transport proteins, located at the basolateral 
membrane of hepatocytes, like Organic Solute Transporter Subunit α, β (OSTα, β), 
Multidrug Resistance-Associated Protein 3 and 4 (MRP3 and MRP4) are expressed at low 
levels in physiological conditions and become up-regulated during cholestasis. Thus, if bile 
acid secretion is impaired, adaptive responses may limit their accumulation inside 
hepatocytes, preventing hepatocellular damage. If these responses are inadequate, cell 
damage and death may occur by either apoptosis or necrosis.  
Of note, bile acids can trigger hepatocyte-specific inflammatory response in cholestatic 
environment that involves increased expression of cytokines such as C-C Motif Chemokine 
Ligand 2 (CCL2), C-X-C Motif Chemokine Ligand 2 (CXCL2), and Interleukin 8 (IL8), which 
in turn can contribute to neutrophil recruitment and augment local inflammation. This 
response is also dependent on the activation of the toll like receptor-9, maybe by BA-
induced mitochondrial damage and consequent releasing of mitochondrial DNA. In 
addition to the local inflammation promoted by bile acids in other scenarios, such as in 
cholangiopathies or diseases of the bile duct, there are other types of related diseases. 
Mechanical obstruction is one of these and leads to an increase in biliary pressure, the 
occurrence of biliary infarcts and the loss of bile acids and other bile components in the 
surrounding tissue that can activate proliferative reactions and hepatic fibrogenesis leading 
to disease progression and finally to cirrhosis 10. 
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1.2 Different etiologies of cholestasis 
Cholestasis is a clinical syndrome that can be either extra or intra-hepatic in etiology and 
springs from diminished bile production by hepatocytes or impaired bile secretion at the 
level of cholangiocyte to obstruction of bile flow by stones (cholelithiasis) or by tumor bulk.  
The common causes of extrahepatic cholestatic liver disease include choledocholithiasis, 
tumors and parasitic infections.  
Several causes of intrahepatic cholestasis include immune-mediated conditions like primary 
biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), exposure to several 
medications (steroids, nonsteroidal anti-inflammatory drugs, antibiotics, anti-diabetic 
agents) and inborn errors as genetic defects in cholesterol and bile acid biosynthesis or 
regarding their metabolism 11. All these syndromes share the retention of products into 
blood or cholangiocytes, instead of being excreted into bile under normal activity. This 
condition of further retention of toxic hydrophobic bile acids cause persistent and extensive 
damage to the bile duct. In addition, depending on the triggering factors and its evolution, 
cholestatic disease is divided into progressive or non-progressive forms. 
To adequately deal with cholestatic injury, it is necessary to first identify and appropriately 
target those defective secretory mechanisms or surgically remove or remediate lesions that 
obstruct or interfere with bile duct patency. The pathogenesis of many cholestatic liver 
disorders has been evolving with most research in bile production and secretion pathways, 
thus several molecular targets for diverse aspects of bile acids signalling and transport have 
been developed recently 5.  
In the next paragraphs follows a description of the progressive forms, which are the subject 
of the PhD thesis, and non-progressive forms of cholestasis. 
 
1.3 Progressive familial intrahepatic cholestasis 
Progressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive 
cholestatic diseases that affects especially new-borns and children. These diseases represent 
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a consolidated indication for liver transplantation 12. These disorders unavoidably 
progressive to liver cirrhosis and portal hypertension. In most severe cases the progression 
to liver failure may occur in the first decades of life. PFIC is considered a rare disease with 
an estimated incidence of 1/50,000 to 1/100,000 births and all types of PFIC exist worldwide 
13; however, their incidence is hard to establish because of difficulties in diagnosis. 
Clayton et al. first described this disease in 1965 as Byler disease in a population of Amish 
kindred 14. The disease has been classified into three types (types 1, 2 and 3) based on the 
genetic defect involved in bile transport 15. The three first described transport proteins 
associated to PFIC disease are familial intrahepatic cholestasis 1 (FIC1, gene symbol: 
ATP8B1), bile salt export pump (BSEP, PFIC2, ABCB11) and multidrug resistance P-
glycoprotein 3 (MDR3, PFIC3, ABCB4). These proteins are all located in the canalicular 
membrane of hepatocytes and mediate bile formation. The FIC1 protein is encoded by the 
ATP8B1 gene and represents a P-type ATPase, which flips aminophospholipids from the 
outer to the inner membrane leaflet, resulting in maintenance of membrane asymmetry, 
which is essential for the function of other canalicular transport proteins. BSEP (ABCB11) 
and MDR3 (ABCB4) are members of the subfamily B (MDR/TAP) of adenosine triphosphate 
(ATP)-binding cassette (ABC) transporters. As already mentioned above, BSEP excretes bile 
salts from the hepatocyte into the bile canaliculus, which represents the major driving force 
of bile salt-dependent bile flow 16. MDR3 protein acts as a floppase and transports lipids of 
the phosphatidylcholine family from the inner to the outer leaflet of the canalicular 
membrane. A reduction or even an absence of FIC1, BSEP or MDR3 functionally active from 
the canalicular membrane of hepatocytes is the molecular mechanism underlying a wide 
spectrum of cholestatic disorders that includes both forms acquired, due to infections or 
drugs and hereditary cholestatic diseases. Mutations in the genes encoding FIC1 or BSEP 
may trigger a typical cholestatic disorder which is associated with normal levels of gamma-
glutamyltransferase (low γ-GT cholestasis). In contrast, MDR3-related cholestasis is 
characterized by elevated γ-GT levels (high γ-GT cholestasis), which may be explained by 
impairment of mixed micelles due to reduced phospholipid concentrations in bile, resulting 
in higher relative concentrations of bile salts in bile with subsequent toxic effects on bile 
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ducts 17. Progressive familial intrahepatic cholestasis (PFIC) type 1, 2 or 3 represent severe 
forms of cholestasis with an early onset phenotype linked to homozygous or compound 
heterozygous mutations in either the FIC1, BSEP or MDR3 genes, often requiring liver 
transplantation in early childhood. Heterozygous variants in these three genes have also 
been linked to milder cholestatic phenotypes or non-progressive forms like benign recurrent 
intrahepatic cholestasis (BRIC), intrahepatic cholestasis of pregnancy (ICP), contraceptive-
induced cholestasis (CIC), drug-induced cholestasis (DIC), or low phospholipid-associated 
cholelithiasis (LPAC) for MDR3 variants 18. Furthermore, late onset phenotypes have been 
described to have mutations in all three genes. It is also interesting that some genes 
responsible for PFIC are involved in the genesis of liver tumors such as hepatocellular 
carcinoma (HCC) and cholangiocarcinoma (CCA).  
In last few years, the development of diagnostic methods such as next-generation 
sequencing (NGS) and whole-exome sequencing (WES) has allowed the detection of new 
genes responsible for PFIC4 and PFIC5. Mutations in TJP2 (coding for tight junction protein-
2) were linked to intrahepatic cholestasis with low GGT (PFIC4). The first association was 
described in 2014 19 and the disease results clinically similar to PFIC2 and caused by 
homozygous or compound heterozygous mutations. Mutations in NR1H4 gene, coding the 
farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor that regulates 
bile acid metabolism, were associated for the first time to neonatal forms of cholestasis 20. 
Finally, mutations in Myosin 5B gene (MYO5B), responsible for a PFIC-like form without 
microvillus inclusion disease, have been reported recently 21. 
In table 1 are represented various aspects of the different forms of PFIC, considering clinical 
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Table 1. Summary of the typical features of progressive familial intrahepatic cholestasis associated with different 
genetic etiologies. Major deficiencies and relative genes involved underlying the different types of PFIC and their typical 
phenotypes. Abbreviations: BSEP: biliary salt export pump; MDR3: class III multidrug resistance P-glycoprotein; TJP2: 
tight junctions protein-2; ZO-2: zona occludens-2; FXR: fanesoid X receptor; MVID: microvillous Inclusion Disease; 
MYO5B: myosinVB protein; RAB11A: RAS-related protein RAB11 A; LT: liver transplantation; ESLD: end-stage liver 
disease; vitK: vitamin K; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma-glutamyl 
transferase; AFP: alpha-1-fetoprotein; BA: bile acids. *MYO5B is classified by OMIM, online mendelian inheritance in man, 
as the gene responsible for microvillus inclusion disease but not yet for PFIC6. Vitale et al. Digestive and Liver Disease 2019. 
 
1.3.1 Progressive familial intrahepatic cholestasis 1 
Progressive Familial Intrahepatic Cholestasis Type 1, also known as PFIC1, ATP8B1 disease, 
OMIM #211600 (OMIM® - Online Mendelian Inheritance in Man) and formerly Byler’s 
disease 14, is the consequence of a severe defect in the gene encoding ATPase, BSEP/FIC1 
(familial intrahepatic cholestasis 1), mapping on the long arm of the 18th chromosome 
(18q21.31) 22, reverse strand.  This gene has a transcript length of 5935 base pairs (bp) 
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(ENST00000536015.1), divided into 28 exons. Its translation leads to a 1251 aminoacids long 
protein (NM_005603) (source: Ensembl genome browser).  
It is a protein widely expressed, found in most tissues except brain and skeletal muscle and 
most abundant in pancreas, small intestine and liver. FIC1 protein acts as lipid flippase, 
carrying phosphatidylserine and phosphatidylethanolamine from ectoplasmic to the 
cytoplasmic leaflet of the hepatocyte canalicular membrane. FIC1 maintains the asymmetry 
between inner and outer leaflet of plasma membrane, having a protective function against 
high concentrations of bile salts. In healthy liver, elevated bile salts levels mediate activation 
of FXR. The FXR induces BSEP expression, thereby stimulating biliary bile salts output.  In 
the intestine, FXR represses apical sodium-dependent bile acid transporter (ASBT) 
expression reducing intestinal bile salts reabsorption. Therefore, reduced FXR expression in 
PFIC1 represents a consequence, rather than a cause, of cholestatic phenotype in ATP8B1 
deficiency. 
The main occurrences are the appearance of cholestasis, usually in the first few months of 
life, recurrent episodes of jaundice associated with uncontrollable itching with low gamma-
glutamyl transferase. Progression to cirrhosis and end-stage liver disease (ESLD) occurs at 
a variable rate. In contrast to the other PFICs (PFIC2-5), clinical manifestation of PFIC1 also 
includes a wide range of extrahepatic symptoms, since the protein is also expressed in apical 
membrane of cholangiocytes, enterocytes and acinar cells of the pancreas. Extrahepatic 
manifestations of ATP8B1 disease include elevated sweat chloride concentrations, delayed 
pubescence and growth, and watery diarrhoea as well as impaired hearing and pancreatitis 
23. These symptoms often persist, while diarrhoea even tends to worsen after liver 
transplantation. Liver allografts in PFIC1 patients may display diffuse steatosis with a 
variable necro inflammatory component, with subsequent fibrosis 24. In fact, in a 2009 study, 
Miyahawa-Hayashino et al. showed that patients with post-transplant steatosis typically 
had more severe mutations in ATP8B1 gene and were more likely to have systemic 
complications such as pancreatitis. Both diarrhoea and steatosis/steatohepatitis may 
improve after biliary diversion 25. 
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Laboratory findings show cholestasis with low serum levels of GGT, increased serum 
concentrations of primary bile salts and normal levels of cholesterol. Aminotransferases, 
starting within the reference range at the beginning of the disease, gradually increase by up 
to tenfold together with disease progression. From the histological point of view there are 
notable changes that mainly involve the canaliculi around the central veins with strong 
cholestatic stress. The interlobular ducts can be hypoplastic due to subnormal bile flow. 
Other features are absence of true ductular proliferation, portal and lobular fibrosis with 
inflammation and, more infrequent, giant cell transformation of hepatocytes (figure 2). 




Figure 2. Familial intrahepatic cholestasis type 1 (FIC1) deficiency. (a) Needle biopsy of a 6-year-old girl with 
bland canalicular cholestasis with pseudorosette formation (arrows) and minimal inflammation. Portal tract 
(arrowheads) with mild fibrosis. (Hematoxylin and eosin stain, x200) (b) Electron microscopy of glutaraldehyde-
fixed tissue: canaliculus distended by coarse, granular ‘‘Byler bile,’’ microvillous loss and swelling of residual 
microvilli. (Uranyl acetate/lead citrate, x8000) Morotti et al. Semin Liver Dis. 2011. 
 
Ursodeoxycholic acid (UDCA) is the main treatment for early therapeutic management in 
children 26. However, if there are also symptoms related to the intestine (including 
pancreatitis), pancreatic enzymes and fat-soluble vitamins are indicated. Cholestyramine 
and rifampicin have also been used for the treatment of the itching. When medical therapy 
fails, the partial biliary diversion (PBD) should be considered and the naso-biliary drainage 
may help to select potential responders to surgery. In approximately 80% of patients with 
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PFIC1 and 2, the partial biliary diversion results in improved growth, normalization or 
improvement of liver function and reduction of fibrosis 27. If the latter are ineffective, liver 
transplantation is the only option but the development of the non-alcoholic fatty liver 
disease (NAFLD) and growth retardation can worsen the quality of life even after surgery 
28. 
1.3.2 Progressive familial intrahepatic cholestasis 2 
Progressive Familial Intrahepatic Cholestasis Type 2, also known as PFIC2, ABCB11 disease, 
(OMIM #601847) is caused by mutations in ABCB11 gene, which is located on the long arm 
of the second chromosome (2q24) and encodes the canalicular transport protein 
ABCB11/BSEP (Bile Salt Export Pump). ABCB11 is a reverse gene and it has a transcript 
length of 4775 bp (ENST00000263817.6), divided into 28 exons. Its translation leads to a 1321 
aminoacids long protein (NM_003742).  
BSEP protein is a liver-specific ATP -binding cassette transporter that mediates the excretion 
of monovalent bile salts from hepatocyte to canaliculi against a concentration gradient 29. It 
is the main transporter of bile salts with a critical role in their physiologic maintenance in 
enterohepatic circulation. Expressed predominantly, if not exclusively in the liver, where it 
is further localized to the canalicular microvilli and to sub canalicular vesicles of the 
hepatocytes.  
Long-term regulation of BSEP is complex and must fulfil many demands. It occurs in large 
parts on the level of transcription. Major regulators of BSEP expression are the farnesoid X 
receptor (FXR), the liver receptor homolog 1 (LRH1, NR5A2 gene, Nuclear Receptor 
Subfamily 5 Group A Member 2) and the nuclear factor erythroid 2-related factor 2 (NRF2, 
NFE2L2 gene). The farnesoid X receptor together with its obligate partner RXRα (Retinoid 
X Receptor Alpha) directly transactivates the BSEP promoter after bile acid binding to FXR. 
Chenodeoxycholate (CDCA), the predominant bile acid in humans, is the most powerful 
natural agonist for FXR. In mice, CDCA facilitates the recruitment of the coactivator 
complex ASCOM (Activating Signal Cointegrator-2 complex), including the coactivator 
NCOA6 and the H3K4 lysine methyltransferase MLL3, leading to methylation of histones 
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within the mouse Bsep promoter region, a process shown to be essential for Fxr-dependent 
Bsep expression 30. The steroid receptor coactivator-2 (SRC-2; also known as nuclear receptor 
coactivator-2 NCOA2 gene) was also shown to cooperatively interact with BSEP promoter 
stimulation by FXR. SRC-2 is activated via phosphorylation by the AMP activated protein 
kinase (AMPK), which is regarded as an energy depletion sensing kinase. SRC-2 possesses 
an intrinsic histone acetyltransferase activity and is recruited to promoter sites of genes. It 
was suggested that the AMPK-SRC2/FXR-BSEP cascade eventually would enhance fat 
absorption from the intestine via increased BSEP-dependent bile salt secretion. The 
importance of SRC-2 was highlighted by the observation that BSEP mRNA and protein 
expression was significantly reduced in hepatocytes-specific SRC-2 knockout mice, whereas 
deletion of SRC-1 or SRC-3 has no effect. The liver kinase B1 (LKB1), also known as 
serine/threonine kinase 11 (STK11), acts upstream of the AMPK and in addition activates 
other kinases from the AMPK-related kinase family. LKB1 regulates cell polarity and, via 
AMPK, cellular energy homeostasis. Interestingly, mice liver-specific knockout of LKB1 led 
to defective bile duct formation, impaired bile acid clearance and a marked retention of 
mBsep in intracellular pools along with reduced Ntcp mRNA (Sodium-taurocholate 





Figure 3. Regulation of the bile salt export pump (BSEP) promoter. Bile acids (BA) are major regulators of BSEP 
expression through activation of the farnesoid X receptor (FXR). The activating complex ASCOM (see text for 
details) is recruited by BA/FXR for the methylation (Me) of histones within the BSEP promoter. The nuclear factor 
erythroid 2-related factor 2 (NRF2) is activated by oxidative stress (e.g. by certain ‘‘toxic’’ BA), binds to a Maf 
recognition element (MARE) and transactivates the BSEP promoter. The steroid receptor coactivator-2 (SRC2) is 
activated by the liver kinase B1 (LKB1) and the ‘‘energy sensor kinase’’ AMP activated protein kinase (AMPK) and 
activates gene expression via acetylation (Ac) of histones. Liver receptor homolog 1 (LRH1) transactivates BSEP and 
CYP7A1, the rate-controlling enzyme of BA synthesis. Increased BSEP transcription eventually increases BSEP 
protein expression and removal of intracellular BA. (FXRE: FXR response element; LRHRE: LRH response element; 
NTCP: Na+-taurocholate cotransporting polypeptide; ROS: reactive oxygen species; RXR: Retinoid X receptor; the 
arrows indicate stimulation/activation; dotted lines represent BA flux.) Kubitz et al. Clin Res Hepatol Gastroenterol. 
2012. 
 
As regards the clinical aspects of PFIC2, they are very similar to PFIC1, but no extrahepatic 
symptoms are present. BSEP deficiency can lead to cholestatic jaundice and itching in the 
neonatal period. Moreover, PFIC2 may leads to gallstone formation and the early increase 
in serum aminotransferases. Another difference with PFIC1, which may have serious 
complications in PFIC2, is that hepatobiliary neoplasms can develop, both hepatocellular 
carcinoma and cholangiocarcinoma 32. Untreated PFIC2 usually leads to progressive liver 
fibrosis and cirrhosis, the development of which is more rapid than in PFIC1. For this 
reason, screening for liver tumours should be performed from the first year of life in patients 
with PFIC2. In liver biopsies of patients with PFIC2 the histology shows severe lobular 
injury, more pronounced lobular/portal fibrosis, inflammation and more severe 
hepatocellular necrosis respect to PFIC1. Another severe complication is giant cell 
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(syncytial) hepatitis with hepatocanalicular cholestasis, while a condition of extramedullary 
hemopoiesis is frequently detectable in the lobules. The interlobular bile ducts can be 
hypoplastic and ductular proliferation is commonly observed at the peripheries of the portal 
triads. A reduced expression or even the absence of BSEP protein at immunohistochemistry 
can help the diagnostic process 33 (figure 4). 
 
 
Figure 4. Histopathology of ABCB11 disease. (a) Giant-cell hepatitis (arrows) with hepatocanalicular cholestasis 
and (b) complete absence of ABCB11/BSEP protein are typical findings in PFIC2 patients. Inset: 
immunohistochemical positivity of BSEP in the apical (canalicular) domain of hepatocytes in a healthy control. (a) 
Hematoxylin and eosin, original magnification x200. (b) Immunohistochemical staining with ABCB11 Rabbit 
Polyclonal Antibody (NBP1-89319, Novus Biologicals, USA), original magnification x200 (b), x400 (inset). Sticova 
et al. Canadian Journal of Gastroenterology and Hepatology 2018. 
 
Ursodeoxycholic acid (UDCA) is also used as one medical therapy option. In a study of 
Gonzales et al. 2015, it has been observed a decrease of pruritus and serum bile acid 
concentration, as well as an improvement of serum liver tests by using 4‐phenylbutyrate in 
patients carrying missense mutations. Pathological liver injuries improved and BSEP 
appeared at the canalicular membrane, where was not been detected before treatment, by 
inducing de novo canalicular BSEP expression 34. This drug was previously used in patients 
with urea cycle defects. One curative method for patients with PFIC2 is liver transplantation 
and, unlike in PFIC1, steatosis and steatohepatitis are not present in liver allografts in the 
case of PFIC2. However, post-transplant PFIC2 phenotype recurrence has been observed, 
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with elevated serum levels of bile salts and bilirubin with almost normal GGT activity. 
Notably, in a patient’s group with very high prevalence of severe BSEP mutations (e.g. splice 
site and premature stop codon mutations), de novo polyclonal inhibitory antibodies directed 
against the first extracellular loop of BSEP have been observed in the post-transplant serum, 
a condition known as Autoimmune BSEP Disease (AIBD) 35. It is estimated that up to 8% of 
transplanted PFIC2 patients develop anti-BSEP antibodies and the exact mechanism by 
which bile salts transport is inhibited by anti-BSEP antibodies is still unknown. 
Interestingly, post-transplant development of inhibitory autoantibodies directed against 
FIC1 and MDR3 transporters with corresponding phenotypes has not been documented yet 
in patients with PFIC1 and PFIC3, respectively. 
 
1.3.3 Progressive familial intrahepatic cholestasis 3 
Progressive familial intrahepatic cholestasis 3, also known as PFIC3, ABCB4 disease, (OMIM 
#602347) is caused by mutations in both alleles or just in one of the ABCB4/MDR3 gene, on 
chromosome 7q21. ABCB4 is a reverse gene and it has a transcript length of 4020 bp 
(ENST00000265723.4) divided into 28 exons too. Its translation leads to a 1286 aminoacids 
long protein. This gene encodes for the phospholipid transporter MDR3 (ATP Binding 
Cassette Subfamily B Member 4 or Multidrug Resistance Protein 3, NM_018849).  
This protein is an energy-dependent phospholipid efflux translocator that acts as a positive 
regulator of biliary lipid secretion. It functions as a floppase that translocates specifically 
phosphatidylcholine from the inner to the outer leaflet of the canalicular membrane bilayer 
into the canalicular lumen of hepatocytes 36. Phosphatidylcholine is a key component of bile 
salts micelles, as it reduces their detergent activity and thus protects the cholangiocytes from 
cellular damage. In fact, translocation of phosphatidylcholine makes the biliary 
phospholipids available for extraction into the canaliculi lumen by bile salt mixed micelles 
and therefore protects the biliary tree from the detergent activity of bile salts 37. Cholestasis 
results from the toxicity of bile in which detergent bile salts are not inactivated by 
phospholipids, leading to bile canaliculi and biliary epithelium injuries. The expression of 
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ABCB4 leads to significant increases in the phosphatidylcholine, phosphatidylethanolamine 
and sphingomyelin contents in nonraft membranes and further enrichment of the latter and 
cholesterol in raft membranes (lipid rafts are specialized domains of cellular membranes 
that are enriched in saturated lipids) 38.  
The age of PFIC3 onset ranges from 1 month to over 20 years. Patients may present less 
aggressive jaundice and itching is often triggered by certain drugs. Other clinical features 
are hepatomegaly, growth retardation and alcoholic stools. As occurs in other PFIC forms, 
there is evidence that either biallelic or monoallelic ABCB4 defects may cause or predispose 
patients to a wide spectrum of human liver diseases: Low Phospholipid-Associated 
Cholelithiasis Syndrome (LPAC), Intrahepatic Cholestasis of Pregnancy (ICP), drug-
induced liver injury (DILI), transient neonatal cholestasis, small duct sclerosing cholangitis, 
and adult biliary fibrosis or slowly evolution to cirrhosis 17. Moreover, hepatocellular 
carcinoma and intrahepatic cholangiocarcinoma have been documented in patients with 
ABCB4 mutations 39.  
Clinical and laboratory findings associated with PFIC3 correspond to the other two forms 
of PFIC described above but are characterised by the absence of extrahepatic symptoms 
(except for cholelithiasis). Unlike PFIC1 and PFIC2, elevated serum GGT activity (often to 
over 10 times the normal value) and normal cholesterol levels are typically observed. The 
serum aminotransferases, conjugated bilirubin, and alkaline phosphatase are variably 
elevated and biliary phospholipids are markedly reduced.  
Liver histology is characterized by non-specific portal inflammation, various stages of portal 
fibrosis, cholestasis with ductular proliferation and by the loss of MDR3 protein expression 
at immunohistochemistry (figure 5). Sometimes, lipid crystals within bile ducts and fibro 
obliterative bile duct lesions can be seen 40. In children the disease may present in the first 
years of life, with early biopsies showing portal fibrosis and ductular proliferation without 
bile epithelial injury or periductal fibrosis. Cholestasis is present as diffuse hepatocellular 
cholestasis, but occasionally canalicular and ductular cholestasis can be present. Later, the 
liver biopsy shows biliary cirrhosis with preserved bile ducts, preserved bile duct 
epithelium, and no significant periductal fibrosis.  
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Like other PFIC forms, medical therapy with ursodeoxycholic acid (UDCA) should be 
considered in the initial therapeutic management of children with PFIC3. UDCA therapy 
may be effective in some patients, especially those with PFIC3 with missense mutations who 
have less severe disease (they respond to treatment with UDCA in 70% of cases) in 
comparison to patients with a mutation leading to a truncated protein. Liver transplantation 
is required in patients with PFIC3-associated liver failure. The mean age of surgical therapy 
is 9.6 years, ranging from 2 to 33 years 17. There are no reports about the use of partial biliary 
diversion in patients with PFIC3. However, drugs that increase MDR3 expression via FXR 
activation could be good candidates for PFIC3 therapy 41.  
 
 
Figure 5. Multidrug resistance protein 3 (MDR3) deficiency. (a) Early: Needle biopsy from a 6-year-old boy with 
fibrous portal expansion and interportal bridging. The lobules contain scattered hepatocellular pseudorosettes 
(arrows). (Hematoxylin and eosin stain; 100) Inset: Portal area with bile ductular reaction (arrowheads) and mild 
chronic inflammation. (x200) (b) Late: Explanted liver from a 12-year-old girl with biliary-type cirrhosis, bile 
ductular reaction and occasional ductular bile plugs (arrow; also seen at higher magnification [x200] in the inset at 
the right lower corner); preserved bile duct (arrowhead); hepatocellular and canalicular cholestasis (better seen in 
the inset at the left lower corner, x200). (Hematoxylin and eosin stain; x40). Morotti et al. Semin Liver Dis. 2011. 
 
1.3.4 Progressive familial intrahepatic cholestasis 4 
The fourth form of PFIC (PFIC4, TJP2 deficiency, OMIM #615878), first described in 2014 19, 
is caused by homozygous or compound heterozygous mutations in the TJP2 gene, located 
in the long arm of chromosome 9 (9q12). TJP2 is a forward strand gene and it has a transcript 
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length of 4500 bp (ENST00000539225.1) divided into 23 exons. Its translation leads to a 1221 
aminoacids long protein (NM_001170416).  
Tight junction protein 2 (TJP2, also zona occludens-2, ZO-2) is a cytoplasmic component of 
cell-cell junctional complexes expressed in most epithelia and, through interaction with 
cytoskeletal proteins and integral membrane proteins, creates a link between 
transmembrane tight junction proteins and the actin cytoskeleton. Human TJP2 gene 
generates 2 isoforms (A and C), both widely expressed. Isoform A is abundant in the heart 
and brain and detected in skeletal muscle. It is present almost exclusively in normal tissues. 
Isoform C is expressed at high level in the kidney, pancreas, liver, heart and placenta and 
does not detected in brain and skeletal muscle, found in normal as well as in most neoplastic 
tissues 42. Complete TJP2 deficiency is associated with a significant reduction in an integral 
tight junction protein, Claudin-1 (CLDN1 gene), predominantly in the canalicular 
membranes of liver cells. This deficiency subsequently leads to the disruption of 
intercellular connections and the leakage of bile through the paracellular space into the liver 
parenchyma 43.  
Immunohistochemical studies 19 using liver tissue do not detected TJP2 protein (figure 6, 
fig. 6a). Claudin-1 and claudin-2 are known to be expressed in the liver and to manifest 
different subcellular localisations and they have been demonstrated to bind to the PDZ1 
domain of TJPs in vitro 44. Immunohistochemical analysis of CLDN1 expression in controls 
showed its presence in tight junction. Staining was substantially reduced in liver tissue from 
patients (fig. 6b). Normal expression of CLDN1 was, however, identified by western 
blotting analysis (fig. 6d). As expected, CLDN2 showed a pericanalicular staining pattern 
in controls. This distribution was preserved in patient material with an apparent increase in 
abundance (fig. 6c). However, western blotting analysis showed normal levels of CLDN2 
protein (fig. 6d). These findings suggest that CLDN1, although expressed, fails to localise in 
the absence of TJP2, whilst CLDN2 localisation is maintained.  
The recently described paediatric cases 19 presented a severe cholestatic disease with normal 
or, at most, slightly increased serum GGT activity and were free of mutations in ATP8B1 
and ABCB11 genes. Those patients displayed severe progressive cholestatic liver disease in 
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early childhood, which puts them at increased risk of developing hepatocellular carcinoma. 
In addition to liver impairment, extrahepatic features have been identified in PFIC4 patients, 
including neurological and respiratory disorders. The PFIC4 onset appeared within 3 years 
in twelve pediatric cases. Nine of twelve patients needed liver transplantation within 10 
years and no recurrences after surgery were observed. All homozygous mutations were 
predicted to abolish protein translation, consistent with a complete loss of function. 
Eighteen of the twenty-nine families examined in this study were consanguineous 19. Until 
then, Zhou et al. in 2015 45 reported 2 patients with PFIC4 who developed hepatocellular 
carcinoma. One was compound heterozygous for TJP2 mutations and the other was 
homozygous for a frameshift mutation. Carlton et al. in 2003 have been previously described 
a single homozygous missense mutation in TJP2 as causing benign familial 
hypercholanemia, a rare disorder of oligogenic inheritance, which usually manifests in 
elevated serum bile salts concentrations, pruritus, and fat malabsorption, but which does 
not lead to the development of liver disease 46. 
 
 
Figure 6. Protein consequences of TJP2 mutation. Immunohistochemical staining of a PFIC4 patient (left panels), 
with control (right panels) for TJP2 (a), CLDN1 (b) and CLDN2/BSEP (c) proteins. TJP2 expression (brown) is absent 
from cholangiocytes and canalicular margins. CLDN1 expression (brown) is markedly reduced at both sites. 
CLDN2 expression (brown), clustered within cytoplasm adjoining bile canaliculi (highlighted by BSEP, red), as has 
been shown previously. Hematoxylin counterstain; scale bar= 100 μm. (d) Western blot for CLDN1 and CLDN2 
proteins isolated from liver biopsy tissues (1 control and 5 patients). Normalization was assessed using GAPDH as 
a loading control. Sambrotta et al. Nat Genet. 2014. 
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1.3.5 Progressive familial intrahepatic cholestasis 5 
PFIC5 (OMIM #617049) is a cholestatic disorder caused by mutations in NR1H4, a gene 
encoding farnesoid X receptor (FXR), the key regulator of bile salts metabolism. FXR is the 
receptor for chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and 
allocholic acid (ACA). NR1H4 gene maps on the long arm of chromosome 12 in position 
12q23.1 and has a transcript length of 1630 bp (ENST00000188403.7), divided in 9 exons, 
producing a 482 aminoacids long protein (NM_001206993). The receptor is predominantly 
expressed in the liver, intestine and to lesser extent in kidney, adipose tissue, muscle and 
adrenal glands. 
The association between NR1H4 mutations and cholestasis has been first described in 2016 
and only 5 patients are reported in the literature. Gomez-Ospina et al. 20 performed whole-
exome sequencing and single-nucleotide polymorphism (SNP) arrays of two unrelated 
probands with severe cholestasis. These analyses revealed homozygous loss of function 
mutations in NR1H4. Subsequently, further analysis confirmed the same NR1H4 genotype 
for an additional affected individual in each family. Consanguinity in one family was 
confirmed by SNP array. 
At the time of initial evaluation all patients had conjugated hyperbilirubinemia, elevated 
aminotransferases, low-to-normal GGT and elevated prothrombin time. Alpha-fetoprotein 
was strikingly increased early in the course of the disease and trended down with time. Two 
of the four patients developed liver failure in the first 2 years of life with worsening 
coagulopathy, hypoglycaemia and hyperammonaemia.  
Histological examination of the liver in all four patients showed ductular reaction, diffuse 
giant cell transformation and ballooning of hepatocytes and intralobular cholestasis (figure 
7). Liver immunohistochemistry showed no detectable expression of BSEP in bile canaliculi 
in all patients, but expression of the phospholipid transporter MDR3 was preserved. 
In another study of 2019, Chen et al. detected the compound heterozygous mutations in the 
NR1H4 gene, c.447_448insA (p.N150Kfs*6) and c.1099C>T (p.R367*) in a female baby born 
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at term with 3 healthy elder brothers with nonconsanguineous parents. The patient died of 
sepsis at age of 5 months, before being able to perform liver transplant 47.  
Since FXR affects several metabolic pathways, some NR1H4 variations or SNPs may be 
associated with susceptibility to various human diseases like gallstone formation, 
differences in glucose homeostasis, ICP, inflammatory bowel disease and several other 
disorders 48.  
 
 
Figure 7. Histological and immunohistochemical findings in NR1H4 mutant livers. Expression of BSEP, MDR3 
and FXR in liver (diaminobenzidine chromogen and hematoxylin counterstain) in patients with NR1H4-related 
cholestasis; normal controls in insets. Hematoxylin/eosin views for orientation. Original magnification, all images, 
x200. BSEP and FXR are absent in all four patients when compared with positive control (inset). MDR3 is present 





1.3.6 PFIC linked to defects in MYO5B gene 
MYO5B is a huge gene and maps on the long arm of chromosome 18 in position 18q21.1 and 
has a transcript length of 9505 bp (ENST00000285039.7), divided in 40 exons, producing a 
protein of 1848 aminoacids (NM_001080467). 
MYO5B gene encodes for myosin-Vb, an actin-associated molecular motor. This protein 
interacts with recycling endosome-associated RAB family proteins, in particular with RAS-
related protein RAB11A. This protein complex is essential for proper functioning of 
polarized epithelial cells, including hepatocytes, such as subcellular positioning of recycling 
endosomes and normal bile canaliculus formation 49. This interaction could be responsible 
for different systemic manifestations. In fact, some patients also suffer short stature, though 
others have normal growth. Some patients with this disease can also have neurologic 
findings, though it is not clear if these are related to the gene defect 50. MYO5B gene 
mutations cause microvillus inclusion disease (MVID, OMIM #251850), a congenital 
disorder of the enterocyte leading to intractable diarrhoea, requiring parenteral nutrition 
and often necessitating intestinal transplantation 51. Cholestasis with normal-range GGT and 
intractable pruritus has been reported as an atypical symptom or as a side effect of 
parenteral nutrition in some MVID patients before or after intestinal transplantation 52. 
Girard et al. in 2014 first described MVID patients developing a cholestatic liver disease akin 
to progressive familial intrahepatic cholestasis, characterized by intermittent jaundice, 
intractable pruritus, increased serum bile acid levels and normal GGT activity. Liver 
histology showed canalicular cholestasis, mild-to-moderate fibrosis, and ultrastructural 
abnormalities of bile canaliculi. No mutation in ABCB11 or ATP8B1 genes were identified 
but immunohistochemical studies demonstrated abnormal cytoplasmic distribution of 
MYO5B, RAB11A, and BSEP proteins in hepatocytes 53. These first results suggested that 
cholestatic disease can arise by impairment of the MYO5B/RAB11A apical recycling 
endosome pathway in hepatocytes, resulting in an altered targeting of ABC transporter 
proteins, (BSEP is one of these) to the canalicular membrane.  
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In the study of Gonzales et al. 2017, they identified four compound heterozygous and one 
homozygous MYO5B mutation in five paediatric patients with normal-GGT PFIC 
phenotype and without clinical bowel disease, in whom other causative gene mutations had 
not been found 54. The age of onset of symptoms was about 1 year and at a median age of 5 
years none of the children have progressed to liver failure nor been listed for liver 
transplantation. Liver histology showed lobular and portal fibrosis, numerous 
multinucleate giant hepatocytes, hepatocellular and canalicular cholestasis and absence of 
bile duct proliferation (figure 8). Interestingly, Qiu et al. also showed a prevalence of 
MYO5B deficiency in 20% of previously undiagnosed low-GGT cholestasis cases in whom 
neither recurrent diarrhoea nor received parenteral alimentation have been reported 21. 
In addition to supportive care for nutrition and diarrhoea, patients have been treated with 
antipruritic and anticholestatic agents, including UDCA, rifampin, cholestyramine, 







Figure 8. Liver histology and BSEP and MDR3 immunostaining studies in two children with MYO5B mutations 
and cholestasis with normal serum GGT activity. (A) Presence of giant hepatocytes (arrowhead) and of canalicular 
cholestasis (arrow). Hematoxylin and eosin, x200. (B) Normal pattern of canalicular expression. Normal human 
liver, BSEP immu-nostaining, x400. (C) Normal pattern of canalicular expression. Normal human liver, MDR3 
immunostaining, x400. (D, F) Presence of an abnormal pattern of expression, with thickened canalicular staining 
and a granular and patchy pattern in the subcanalicular area. BSEP immunostaining, x400. (E, G) Presence of an 
abnormal pattern of expression, with thickened canalicular staining and a granular and patchy pattern in the 





1.4 Non-progressive familial intrahepatic cholestasis 
1.4.1 Benign recurrent intrahepatic cholestasis  
Benign recurrent intrahepatic cholestasis (BRIC) is a group of genetically heterogeneous 
autosomal recessive disorder, characterised by intermittent episodes of cholestasis. BRIC is 
caused by homozygous or compound heterozygous mutations in ATP8B1 and ABCB11 
genes. For this reason, it is divided into two different phenotypes: BRIC1 (Summerskill-
Walshe-Tygstrup syndrome, OMIM #243300) and BRIC2 (OMIM #605479), caused by partial 
deficiency in ATP8B1 56 and ABCB11 57.  
The symptoms and physical aspects of BRIC are summarized in table 2. Typical clinical 
manifestations are pruritus and jaundice. One fourth of patients may never develop pruritus 
while in others the scleral icterus is barely noticeable. Other common symptoms include 
illness, irritability, nausea, vomiting, and anorexia. A small percentage of patients 
experience fever, arthralgias, headaches, and urticaria. Steatorrhea caused by fat 
malabsorption and anorexia can lead to significant weight loss during prolonged episodes 
of cholestasis. Other complications dependent on vitamin K malabsorption are 
coagulopathy and haemorrhagic complications such as bruising, epistaxis, vaginal and 
gingival bleeding 58. 
The first attack of pruritus and jaundice typically occurs during the patient’s teens, twenties 
or more, with itching that usually anticipates the appearance of jaundice (by 2 to 4 weeks). 
The duration and number of attacks vary widely in each patient and each attack can last 
from 2 weeks to 18 months. The mean duration is approximately 3 months. During the 
patient's life, there can be up to thirty attacks. Between each attack, asymptomatic periods 
range from as little as 1 month to as long as 33 years and the average frequency of attacks is 
slightly more than once every 2 years. The triggering factors can be the pregnancy, the 
infections or drugs such as oral contraceptives. Biochemical findings during cholestatic 
attacks reveal increase of bilirubin and bile salts levels in serum, while GGT activity and 
serum cholesterol levels tend to be normal. Enzyme levels of aminotransferase activity are 
usually in normal fields or slightly increased, while biochemical parameters fall within 
29 
 
normal ranges. Liver biopsies performed during cholestatic attacks have demonstrated 
hepatocanalicular cholestasis without fibrosis, while tissue expression of BSEP is reduced 
or mostly maintained at immunohistochemistry in BRIC2 57. During the asymptomatic 
period, the histological features are completely normal.  
 
 
Table 2. Symptoms and physical findings of BRIC during symptomatic and asymptomatic periods. 
 
 
To perform a differential diagnosis for BRIC is necessary to exclude other diseases that could 
be overlapping or related to cholestatic manifestations, as the extrahepatic biliary 
obstructions, the acute viral hepatitis, the autoimmune hepatitis, and the immune-related 
cholestatic disorders 15. After clinical exclusion of other diseases, molecular diagnosis of 
BRIC1 and BRIC2 should be done, demonstrating evidence of mutations in both alleles of 
the corresponding genes, ATP8B1 and ABCB11.  
While mutations causing PFIC are often located in the conserved regions of the genes that 
encode for important functional domains of the corresponding proteins, mutations in BRIC 
usually only partially impact protein function and expression. However, several cases of 
initially benign episodic cholestasis that have subsequently transitioned to a persistent 
progressive form of the disease have been reported, especially if the disease has an early 
onset. Van Ooteghem et al. in 2002 described four infant patients in whom liver biopsies 
performed in the early stages of the disease showed normal liver architecture, while late 
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stage biopsies revealed evident fibrosis with porto-portal septa formation 59. Thus, BRIC and 
PFIC seem to represent two extremes of a continuous spectrum of phenotypes of the one 
disease.  
The treatment of BRIC is symptomatic and aims to reduce the frequency of the cholestatic 
attacks and to prevent the relapses. The administration of statins, corticosteroids, 
cholestyramine, or ursodeoxycholic acid (UDCA) is usually not very effective in BRIC 
patients. In this regard, rifampicin, antihistamines, phenobarbital and carbamazepine have 
been proposed in recent years. Nevertheless, severe hepatotoxicity after long-term 
administration of rifampicin has been reported in patients with cholestatic disorders 60, 61. 
Non-medical treatments include short-term naso-biliary drainage, which can improve the 
pruritus and reduce the duration of cholestatic attacks 62.  
 
1.4.2 Intrahepatic Cholestasis of Pregnancy 
Intrahepatic cholestasis of pregnancy (ICP, OMIM #147480), also called obstetric cholestasis, 
is the most common liver disease of the pregnancy. It is a liver condition of pregnancy 
characterized by pruritus and the biochemical finding of elevated serum bile acids, often in 
the presence of other signs of liver dysfunction. By definition, ICP is confined to pregnancy 
and the peripartum period and usually resolves soon after delivery. It is diagnosed after 
exclusion of other causes of cholestasis. In addition to the maternal symptomatology, ICP 
can be associated with adverse fetal outcomes: spontaneous preterm birth and meconium 
staining of the amniotic fluid can be registered especially in ICP patients with high levels of 
bile salts (>40  mol/L), while the risk of stillbirth is increased when serum bile salts 
concentrations are ≥100 mol/L 63; hence, appropriate recognition and management are 
extremely important.  
Several studies confirmed ICP to be characterized by glucose intolerance and dyslipidaemia, 
consistent with the changes observed in the metabolic syndrome. This adverse effect was 
secondary to maternal aberrant bile acid homeostasis. From the 12th week of pregnancy, 
lipid parameters, including total cholesterol, triglycerides, low-density lipoprotein-
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cholesterol (LDL) and high-density lipoprotein-cholesterol (HDL) are increased, especially 
in the second and third trimesters 64.  
The incidence of ICP ranges from 0.1% to 15.6% worldwide and it is dependent on 
geographic location and ethnicity. For example, the incidence is 4% in Chile; in the United 
Kingdom it is 0.7% but is higher in women of Indian or Pakistani origin, whereas the 
incidence in China has recently been estimated at 1.2%, based on more than 100,000 hospital 
births. Within the Californian population, genetic ancestry mapping has indicated higher 
levels of ICP in women of Native American ethnicity 65.  
The heterozygous mutations in ATP8B1, ABCB11 and ABCB4 genes in ICP have been 
reported 66. Mutations in ABCB4 were the first to be described in ICP and are implicated in 
up to 20% of ICP cases. In ABCB11 gene, polymorphism c.1331T>C (p.V444A) in exon 13, 
has been consistently observed in pregnant women 67. It was reported in 83% of Caucasians 
with ICP and the susceptibility to this disorder was increased if combined with other 
mutations in the same gene or in the other two for PFIC1 and PFIC2.  
The heterozygous mutations have also been identified in ATP8B1 gene during ICP, but just 
few cases are described 68. Another gene involved in PFIC5, NR1H4, has been previously 
associated with the ICP. Van Mil et al. identified 4 novel heterozygous FXR variants (c.-1G>T, 
p.M1V, p.W80R, p.M173T) in ICP. They demonstrate functional defects in either translation 
efficiency or activity for 3 of the 4 variants (c.-1G>T, p.M1V, p.M173T), suggesting a 
predisposition of those alleles for ICP 69. In an ICP cohort of 147 women Dixon et al. have 
identified some evidence for involvement of TJP2 gene, with three occurrences of variants 
where bioinformatics prediction tools did not agree on the clinical relevance of these 
changes but that may predispose to the disease 70.  
Differential diagnosis should include other causes of jaundice such as HELLP syndrome (a 
pregnancy-associated disease characterized by Haemolysis, Elevated Liver enzymes, and 
Low Platelets in the mother), acute fatty liver of pregnancy, viral hepatitis, Budd–Chiari 
syndrome and Primary Biliary Cholangitis 15. Cholestyramine, dexamethasone, S-Adenosyl-
l-methionine, rifampicin and UDCA have been used as medical therapy in ICP. The UDCA 
represents the first-line therapy being able to reduce maternal and fetal complications of 
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ICP, improving maternal symptoms and biochemistry values. Pregnant women with 
previous ICP and fetal mortality should start UDCA therapy early in subsequent 
pregnancies 71. The rifampicin, a potent pregnane-X receptor agonist, has reported to be 
useful as a second line therapy in one third of pregnant women not responsive to UDCA 
alone. S-Adenosyl-l-methionine improves itching in the mother while dexamethasone 
promotes only the fetal lung maturity. Oral contraceptives represent a risk factor for further 
liver impairments in women having past ICP history. Usually, in presence of ICP phenotype 
and when the clinical picture in well established, physicians induce the birth between 37 
and 38 weeks of gestation to reduce the risk of intrauterine death. Although the blood tests 
and liver parameters are usually normalized within 2–8 weeks after delivery, a follow-up is 
necessary for ICP patients because these women may continue to have liver disfunctions, 
with the possibility to develop cirrhosis, non-alcoholic pancreatitis and cholelithiasis 
overtime 72.  
 
1.4.3 Drug induced cholestasis 
Drug-induced liver injury (DILI) is caused by a different number of triggering factors, 
including drug-induced cholestasis (DIC) and it is another form of acquired liver disease, 
accounting for approximately 2 to 5% of hospitalizations for jaundice, 10% of cases of 
hepatitis in all adults, and more than 40% of hepatitis cases in adults older than 50 73. 
Approximately 30% of DILI are from cholestatic origin.  
The liver pathology of drug-induced liver injury covers a wide spectrum of lesions from 
bland cholestasis to hepatitis and mixed forms. It occurs with many drugs through a variety 
of mechanisms, which might differ in their clinical presentations, ranging from 
asymptomatic mild biochemical abnormalities to an acute illness with jaundice that 
resembles viral hepatitis. Although good epidemiologic data exist on the entire spectrum of 




Cholestatic liver injury is typically characterized by a predominant elevation in alkaline 
phosphatase and bilirubin levels. Bland canalicular cholestasis is typically associated with 
minimal hepatocellular inflammation and normal or only slightly elevated 
aminotransferase levels and is often seen with anabolic steroids or oral contraceptives. In 
contrast, portal inflammation is seen in hepatocanalicular cholestasis, often associated with 
an elevation of aminotransferases. Acute or chronic hepatitis can be clinical manifestations 
of DIC. Sometimes the itching, the xanthomas and/or the melanoderma are present.  
The main limit during the systemic clearance of lipophilic drugs and their metabolites by 
the liver is their excretion into the bile. Several ATP-dependent canalicular transporters 
regulate this process: BSEP protein (ABCB11), the multidrug resistance protein-2 (MRP2, 
ABCC2 gene) able to cause bile salts independent flow by excretion of glutathione, the 
multidrug resistance-1 protein (MDR1, ABCB1) which transports organic cations and the 
MDR3 protein (ABCB4).  
The list of the drugs that can induce cholestasis includes the non-steroidal anti-
inflammatory drugs, antihypertensives, antidiabetic, anticonvulsants, lipid-lowering 
agents, and psychotropic drugs 74. Many drugs cause cholestasis through the interaction 
with hepatic transporters. To date, a relatively strong association between DIC and 
attenuated BSEP activity has been proposed. Inhibition of BSEP due to a drug activity, 
should lead to reduced bile salts secretion and their retention within hepatocytes, leading 
to cholestasis. The drugs such as rifampicin, cyclosporine A, rifamycin, bosentan, 
troglitazone, erythromycin, glibenclamide inhibit the BSEP protein with a dose-dependent 
action. Chlorpromazine, imipramine, itraconazole, haloperidol, ketoconazole, sequinavir, 
clotrimazole, ritonavir and troglitazone restrain the MDR3 activity in vitro, and resulting in 
an exposure of the biliary epithelium to the toxic detergent effects of bile salts, thus 
increasing susceptibility to DIC or to the vanishing bile duct syndrome.  
The diagnosis of DIC can be difficult, due to the presence of the concomitant medications or 
of other chronic liver diseases 75. The diagnosis of DIC is dependent on the accurate clinical 
history: the use of drugs, herbal remedies and naturopathic substances should be always 
investigated. Temporal relationships between taking the drug and development of liver 
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injury can be different, ranging from a few days to several weeks or longer (1–12 months). 
Furthermore, the use of mixed pharmacotherapies increases the risk of drug-drug 
interactions. The differential diagnosis should be made versus primary biliary cholangitis, 
sepsis, autoimmune hepatitis and obstructive biliary diseases. Liver biopsy may be helpful 
when the diagnosis is difficult; a loss of BSEP/MDR3 expression at immunohistochemistry 
increases the chance for DIC diagnosis. In DIC, the canalicular cholestasis and minimal 
hepatocellular inflammation are present. Given the different presentation patterns of DIC, 
its management should not be limited to the discontinuation of a specific drug but should 
include genetic analysis to determine which bile transporters variants might be involved, in 
order to avoid relapses of DIC. The most associated disease-causing mutations and 
polymorphisms are in ABCB11 and ABCB4 genes, but it cannot be excluded that other genes 
responsible for PFIC are involved in DIC. 
 
1.4.4 Low phospholipid-associated cholelithiasis 
Low phospholipid-associated cholestasis and cholelithiasis (LPAC or Gallbladder Disease 
1, GBD1, OMIM #600803) is a syndrome first described in 2001 by Rosmorduc et al. The 
disorder is caused by mutations in FIC genes, in particular in the ABCB4 gene, which 
encodes the bile canalicular protein MDR3. In their initial observations, Rosmorduc et al. 76 
described six patients (two men and four women, aged 26-55 years) with a peculiar form of 
intrahepatic cholelithiasis and a family history of gallstones. All six had a mutation in 
ABCB4, and all exhibited remarkable improvement on treatment with ursodeoxycholic acid. 
The exact prevalence of LPAC remains unknown. The disease is more common in young 
adults, the usual age at the onset of the symptoms is typically lower than 40 years. The male 
to female ratio is estimated at approximately 1:3. Up to 10% of the European and American 
population carry gallstones, approximately 25% of cases have symptoms and less than 2% 
present with severe complications (cholangitis or pancreatitis). Based on previous 
epidemiological data, it is considered that LPAC syndrome is infrequent and corresponds 
to a peculiar subgroup of patients with symptomatic gallstone disease. The LPAC is usually 
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associated with the intrahepatic biliary lithiasis and is often symptomatic after 
cholecystectomy and presents a good response to ursodeoxycholic acid. A reduced secretion 
of phospholipids in the bile decreases the solubility of cholesterol promoting its 
crystallization and the gall-stone formation.  
At least two of the following criteria are necessary for the diagnosis of LPAC: (1) age at onset 
of biliary symptoms ≤40 years; (2) intrahepatic echogenic foci or microlithiasis; (3) recurrence 
of biliary symptoms after cholecystectomy. Severe biliary complications such as acute 
pancreatitis, recurrent cholangitis, segmental spindle-shape dilatation of the biliary tree 
filled with gallstones, and ICP may be observed in some patients 77. The diagnosis should 
also be suspected when previous episodes of intrahepatic cholestasis of pregnancy and a 
family history of gallstones in first-degree relatives are present. The onset of the symptoms 
has been reported at the end of or soon after pregnancy. In fact, 56% of symptomatic women 
who are carriers of ABCB4 variants also presented a history of ICP. The cholestasis results 
in an increase of GGT while abdominal ultrasonography, computing tomography scan and 
magnetic resonance cholangiopancreatography, help to evidence the intrahepatic gallstones 
(table 3). In a large cohort of 156 patients, Poupon et al. 78 discovered the ABCB4 variants in 
79 cases (63 heterozygous variants): similar features between subjects with and those 
without mutations were found and the authors hypothesized the possible involvement of 
unexplored genes. For example, the FXR regulates ABCB4 and ABCB11 expression and a 
down-regulation of this gene, due to the mutations or to the high levels of the progesterone 
metabolites, could promote defective bile salts and phospholipid secretion, leading to LPAC 
and ICP. While the homozygous variants cause PFIC3, the heterozygous variants lead to 
LPAC/ICP disorders. The differential diagnosis should be made versus inflammatory 
cholestatic disorders which may cause biliary symptoms and/or intrahepatic gallstones such 
as Caroli disease and primary sclerosing cholangitis. A definitive diagnosis is obtained by 
ABCB4 gene analysis. A careful management is recommended and an indication to 
cholecystectomy should consider high rates of recurrence after surgery. Moreover, a long-





Table 3. Laboratory, clinical, genetic and histological characteristics of different non-progressive familial 
intrahepatic cholestasis. BRIC: benign recurrent intrahepatic cholestasis; ICP: intrahepatic cholestasis of pregnancy; 
DIC: drug induced cholestasis; LPAC: low-phospholipid-associated cholelithiasis; BSEP: biliary salt export pump; 
MDR-3: class III multidrug resistance P-glycoprotein; TJP-2: tight junctions protein-2; zo-2: zona occludens-2; FXR: 
fanesoid X receptor; MYO5B: myosinVB protein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; 
GGT: gamma-glutammyl transferase; ALP: alkaline phosphatase; AFP: alpha- 1-fetoprotein BA: bile acids. Vitale et al. 
Digestive and Liver Disease 2019. 
 
1.5 Current therapeutic options 
1.5.1 Medical therapy 
In addition to the intake of fat-soluble vitamins to prevent deficiencies, two drugs can be 
used: ursodeoxycholic acid (UDCA) and rifampicin.  
UDCA is safe and without major side effects and stimulates hepatobiliary secretion of bile 
salts and it can improve bile flow. Through a complex network of signalling pathways, it 
stimulates the impaired targeting of transport proteins as BSEP or the MRP2 conjugate 
export pump (protein 2 associated with multidrug resistance, coded from ABCC2) to the 
canalicular membrane by activation of a complex signalling network 61. Moreover, UDCA 
conjugates can have antiapoptotic effect, contributing to the protection of hepatocytes. 
UDCA therapy is the first used drug for PFIC. It has been shown that UDCA is effective in 
more than half of the patients with PFIC3 (high GGT). In patients with low-GGT PFIC, the 
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response to UDCA therapy was less promising, but still resulted in improvement of serum 
transaminase levels and pruritus in some patients 79.  
Rifampicin might work, at least in part, by upregulating detoxification enzymes and export 
pumps by mechanisms dependent of pregnane X receptor. In low-GGT PFIC patients, 
rifampicin treatment does not result in improvement of serum transaminases and bilirubin 
and reduces pruritus in only a few patients 61.  
Recently, serotonin reuptake inhibitors were suggested for the management of refractory 
cholestatic pruritus in patients with PFIC or Alagille syndrome, resulting in an 
improvement of this symptom 80. Since no severe adverse events were reported in this 
group, serotonin reuptake inhibitors like sertraline could be considered for uncontrolled 
pruritus. 
Another non-surgical intervention is nasobiliary drainage, a temporary diversion of bile 
established by endoscopically introducing a nasobiliary drain 81. Due to the temporary 
character, this therapy is especially useful to abort long-term cholestatic episodes in BRIC 
patients. The risk of procedure-related pancreatitis needs to be considered. 
 
1.5.2 Surgical therapy 
The purpose of partial biliary diversion (PBD) is to reduce the enterohepatic circulation of 
bile salts, thereby diminishing the accumulation of these compounds and preventing 
hepatic injury. Currently, PBD is therapy of choice in all non-cirrhotic children with low-
GGT PFIC, in whom permanent cholestasis and intractable pruritus is present. This 
intervention was introduced in 1988, as partial external biliary diversion (PEBD) by 
cholecystojejunocutaneostomy 82. This technique has the aim to reduce the reabsorption 
surface, directly secreting bile acids. In up to 85% of the non-cirrhotic patients, PEBD is 
successful in improving pruritus as well as biochemical parameters of cholestasis such as 
serum bile acids, liver enzymes and bilirubin and long-term results indicate that PEBD can 
delay or even reverse hepatic injury. However, the more severe disadvantage of this surgical 
intervention PEBD is that patients must live with a permanent stoma 80.  
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Liver transplantation is indicated for patients with advanced liver disease or persistent 
uncontrolled pruritus, in whom PBD have had no effect. Living-donor liver transplantation 
is also a safe and effective option. PFIC1 patients with ATP8B1 deficiency usually have 
extrahepatic manifestations, due to the widely expression of FIC1 protein. This situation can 
cause significant morbidity even after transplantation. Features such as pancreatitis, short 
stature and hearing loss will persist, and diarrhoea can be induced or exacerbate. ATP8B1 
is highly expressed in the small intestine where it might have a role in the regulation of 
reabsorption of bile salts. After transplantation, normal amounts of bile salts are excreted 
by the hepatic graft while intestinal ATP8B1 is still impaired, resulting in high 
concentrations of bile salts in the colon and subsequent diarrhoea. Furthermore, significant 
hepatic steatosis often occurs after transplantation which can progress to cirrhosis and may 
require re-transplantation 80. Liver transplantation usually gives complete correction of 
phenotype in patients with ABCB4 and ABCB11 deficiency. However, in some patients with 
severe ABCB11 deficiency, recurrence has been observed post liver transplantation as a 
result of the formation of autoantibodies against BSEP. 
 
1.6 Future therapeutic options 
1.6.1 Total biliary diversion 
In some patients, PBD is not effective in reducing clinical symptoms and improving 
biochemical parameters. For these patients, total biliary diversion (TBD) might be useful. In 
four patients with ATP8B1 deficiency, of which three did not benefit from PEBD, total 
external biliary diversion resulted in a significant reduction or complete disappearance of 
pruritus and cholestasis 83. No clinical signs of fat malabsorption were encountered, 
although fat soluble vitamin levels turned out to be more difficult to manage than in PBD. 
Currently, TBD is not recommended as primary therapy since PBD is already effective in 
most of the patients and the experience with TBD is limited to only few patients. Moreover, 
the long-term effects of total absence of intestinal bile salts are unknown. 
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Recently, biliary diversion has also been used in combination with liver transplantation to 
improve diarrhoea and nutritional status in two patients with severe ATP8B1 deficiency, 
which proved to be effective in terms of clinical, histological and biochemical outcomes 84.  
 
1.6.2 Hepatocyte transplantation 
Given the shortage of donor organs, hepatocyte transplantation might become an 
alternative to liver transplantation. Advantages of hepatocyte transplantation are that the 
procedure is less invasive, can be repeated several times and leaves the native liver in situ. 
The procedure may delay or even eliminate the liver transplantation. However, scarcity of 
donor hepatocytes again is the limiting factor. In addition, immunosuppression with its 
associated morbidity is still necessary. Therefore, alternative cell sources are being 
investigated, such as induced pluripotent stem cells (iPSCs) derived hepatocyte-like cells or 
hepatocytes generated by trans-differentiation. Takebe et al. succeeded in generating 
vascularized and functional human liver from iPSCs by transplantation of three-
dimensional liver buds created in vitro 85. However, the hepatocyte-like cells were not fully 
differentiated (absence of cholangiocytes), as evidenced by lower albumin secretion and 
lower expression of hepatocyte specific CYP450 enzymes compared to primary human 
hepatocytes. 
A promising alternative approach is the clonal expansion of single Lgr 5+ bipotent liver 
progenitor cells into transplantable liver organoids 86. A three-dimensional culture system 
allows long-term clonal expansion of single Lgr5(+) stem cells into transplantable organoids 
(budding cysts) that retain many characteristics of the original epithelial architecture.  In 
contrast to iPSC derived hepatocytes or liver buds, the organoid cells are obtained directly 
from the liver without the need for genetic modification or introduction of reprogramming 
factors, diminishing the risk of malignancies. Although several issues need to be addressed, 





1.6.3 Gene therapy 
Gene therapy corrects the defective gene responsible for disease development and can be 
applied to different tissues. However, multiple barriers are still present, including the vector 
genome and transcriptional persistence as well as the immune response that can limit the 
viability of transduced cells 80. In addition, genes like ATP8B1 and ABCB11 are large and 
therefore difficult to insert into conventional viral vectors. Alternatively, autologous 
transplant with ex vivo genetically corrected stem cells or hepatocyte-like cells generated 
from patient derived iPSCs, may hold promise of success. Because liver organoids can be 
based on the in vitro expansion of a single progenitor cell, these might also be suitable for 
genetic modifications. Also in vivo gene editing using the bacterial CRISPR/Cas system 
might become an option in the future 87. 
 
1.7 Sequencing analysis 
1.7.1 Next-generation sequencing 
The development of Next-Generation Sequencing (NGS) technology has enormously 
increased the possibility of genome analysis, having the ability to perform numerous 
measurements simultaneously. In fact, all the NGS platforms available today present a 
common technological feature, the massive parallel sequencing of cloned amplified DNA 
molecules. Sequencing in NGS technologies is performed by repeated cycles of nucleotide 
extensions or by iterative oligonucleotide ligation cycles. Considering the ability of these 
platforms to work in parallel, these tools have the possibility of sequencing from hundreds 
of Mb (millions of base pairs) up to Gb (billions of base pairs) of DNA in a single analytical 
session, according to type of NGS technology used 88.  
NGS technologies involve a series of subsequent steps (§ 2.4) and the unique combination 
of specific protocols distinguishes one technology from the others and determines the type 
of data produced by each platform. In this PhD project Ion Torrent platform was used. 
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1.7.2 Ion Torrent technology 
The Ion Torrent platform uses semiconductor technology: the heart of the platform is 
represented by a semiconductor chip containing an array of millions of ISFET ion sensor 
positioned under as many micro-wells (an ISFET is an ion-sensitive field-effect transistor, 
that is a field-effect transistor used for measuring ion concentrations in solution). Each 
micro-well can accommodate only a single sphere (bead) containing multiple copies of the 
same single-strand DNA (ssDNA). The principle behind platform is the sequencing-by-
synthesis. During the synthesis, the incorporation of a nucleotide complementary to the 
target sequence by the polymerase produces the release of two waste products: the 
pyrophosphate (PPi) and hydrogen ions (H+). A microwell containing a template DNA 
strand to be sequenced is sequentially flooded with a single species of deoxyribonucleotide 
triphosphate (dATP, dTTP, dCTP, or dGTP). A dNTP will only be incorporated if it is 
complementary to the leading unpaired template nucleotide. Whenever a single dNTP is 
added to the growing chain of the ssDNA template, pH-sensitive semiconductors below 
each well detect the increase in protons (figure 9).  The pH lowering, caused by the increase 
in H+ ions generates a current increase in the sensitive surface that is converted into a 
potential variation 89. After the chip is flooded with a single type of dNTP, the signal is 
recorded and follows a wash that restores the initial pH conditions. This step is necessary 





Figure 9. Overview of sequencing using a semiconductor pH sensor device. (A) The sequencing chemistry 
configuration, with templated DNA bead (brown sphere) deposited in a well above the ISFET sensor. The clonally 
templated bead is single-stranded, primed for extension and bound with polymerase. After dNTP incorporation, 
H+ ions are released. The resulting H+ release (Delta pH) is converted into a +charge buildup (ΔQ) on the sensing 
layer, which the conductive “via” metal pillar transmits as a voltage change (ΔV) at the transistor gate. This in turn 
gates the transistor current, and the time-accumulated current signal is sent off-chip, in the form of a voltage signal, 
via a chip-wide polling process. (B) These pH signals are sampled from the well at high frequency (blue curve), e.g. 
100 Hz, and then fit to a model that extracts the net signal (red curve). (C) The net incorporation signals for each 
flow become the primary input, reflecting no incorporation, 1-mer incorporation, 2-mer incorporation, etc. for each 
trial flow, and these raw data are the input for the base calling algorithm that converts the full series of net 
incorporation signals for that well, over hundreds of trial nucleotide flows, into one corresponding sequence read 
(Merriman et al. Electrophoresis 2012).  
 
In this way, the reconstructed sequence will be the result of positive or null signals each 
addition of dNTP. The received signals are shown graphically (figure 9c), with the type of 
dNTP added to the chip in a sequential manner in the abscissa and in ordinate the quantity 
of signal recorded at each incorporation (base calling). In case of homopolymers, in fact, 
there will be more incorporations of the same dNTP and therefore a greater pH variation 
will be recorded (height of each bar). 
The number of sensors in the chips determines its sequencing capability and, therefore, the 
number of reads reproducible at each analytical session. Increasing sequencing capabilities 
can be achieved by increasing the chip area and decreasing the distance between various 
sensor arrays.  
In this study we used two different instruments: Ion PGMTM and Ion GeneStudioTM S5 
System (Thermo Fisher Scientific, Waltham, MA, USA, US). Each instrument has its specific 
chips. For Ion PGM system there are three different chips: 314, 316 and 318. For our purpose 
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we adopted the last one, a chip characterized by an output of 1 Gb (Ion 318), implementing 
several times the sequencing capability of the first chip. 
The Ion GeneStudio S5 systems is the evolution of the Ion PGM and is designed to enable a 
broad range of targeted next-generation sequencing (NGS) applications with speed and 
scalability. Five Ion S5 chips enable a sequencing throughput range of 2M to 130M reads per 
run. The new Ion 550 Chip generates 100–130 million sequencing reads on the Ion 
GeneStudio S5 Plus and Prime Systems and it is not compatible with Ion GeneStudio S5 
System. For the second part of the PhD project, when we updated our NGS panel with 15 
genes (§ 2.10), we had to use the Ion 520TM chip, with up to 8 million reads per run. 
 
1.8 Project aim 
The goal of this project is to develop and validate a broad, reliable, rapid and cost-saving 
genetic test for PFIC patients, based on NGS technology, with a sensitivity comparable with 
Sanger sequencing. 
Up to date, Sanger sequencing represent the most used method in molecular diagnostics. 
However, considering the new large panel size, the probability to have also other genes 
involved in PFIC and the molecular complexity of the disease, like high allele heterogeneity 
and changes in normal autosomal recessive hereditary manner, Sanger method has become 
not suitable for these complex diseases, technically challenging, labour intensive and costly. 
This innovative test may be useful for the molecular diagnostics of PFIC and a better 
characterization and understanding the linking between molecular defects and different 
subtypes of the disease. NGS method guarantees to reach quickly medical reports for all 
patients and their related, so should have great consequences on disease management, 
patient treatment and national medical system. 
Italian adult population data lack clinical significance of mutational profiles of the four 
genes associated to PFIC so far. With this purpose we wanted to perform a screening for 
these genes and assess the role of genetic contributions in an adult cohort, to show that 
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heterozygous mutations are mainly linked to a later onset of the disease or to patients with 
cryptogenic cholestasis.  
In addition, another aim was to find potential alterations on other eleven genes (fifteen-gene 
panel) probably involved in cholestasis and to evaluate their impact on the disease. 
Lastly, the integration of standard variant prediction and classification tools with more 
advanced bioinformatic analyses, to get a deeper understanding on the role of genetic 





SECTION II: MATERIALS AND METHODS  
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2.1   Patients recruitment 
Patients to be included in the project were selected by the S. Orsola-Malpighi Policlinic 
clinicians who mostly deal with cholestatic disease. The groups are mainly: Prof. Fabio 
Piscaglia, dr. Laura Gramantieri, dr. Giovanni Vitale and Prof. Maria Cristina Morelli from 
Internal Medicine Operational Unit, Prof. Pietro Andreone from Internal Metabolic 
Nutritional Medicine of the Policlinic of Modena.  
In the enrolled patients, other causes of cholestasis that cannot be ascribed to the PFIC 
phenotype were excluded, such as primary biliary cholangitis, primitive sclerosing 
cholangitis, viral hepatitis, alcohol abuse, hemochromatosis, Wilson disease and alpha-1-
antitrypsin deficiency. Instead, patients presenting the classic forms of PFIC were included, 
but also BRIC, LPAC, ICP and DIC phenotypes. During the three-year PhD project, from 
December 2016 to August 2019, 176 patients were recruited. All patients signed a specific 
informed consent for genetic analysis for diagnostic purposes.  
 
2.2   DNA extraction and normalization 
The genomic DNA of the patients to be analysed was extracted from peripheral blood 
lymphocytes in EDTA (Ethylenediaminetetraacetic Acid) using the Maxwell® 16 Instrument 
automatic extractor and the related Maxwell® 16 DNA Purification kit (Promega). The 
automatic extractor is prepared for the simultaneous extraction of genomic DNA of 16 
samples in just over 30 minutes, using a system of magnetic beads (MagneSil® Paramagnetic 
Particles) to capture DNA. The specific purification kit consists of disposable cartridges, 
divided into various sections containing the necessary reagents, from disposable plungers 
to cuvettes in which the extracted samples are collected (figure 10).  
The extraction process develops through successive phases, each taking place at a specific 
section of the cartridge. The first step is represented by the cell lysis, which takes place partly 
chemically and mechanically. In the second section of the cartridge, magnetic spheres can 
bind nucleic acids. At this point the plunger is loaded with marbles and then reinserted into 
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the first compartment of the cartridge, where it collects the DNA. After, DNA undergoes to 
purification steps. Finally, the DNA is eluted in a cuvette containing 300 μl of Milli-Q® water 




Figure 10. Maxwell® 16 Extractor. A. 
Instrument. B. Disposable cartridge with 
plunger facing the operator. C. Seen from the 
top of the cartridge, in position 1, where the 
lysis buffer is located, the blood sample is 
loaded, in the well number 7 the eluted DNA 
will be collected after about 30 minutes. 
 
The extracted DNA samples were quantified using the Nanodrop 3.0.0 spectrophotometer 
(Celbio S.P.A. Milan, Italy). This instrument, using 1 μl of DNA, allows to determine the 
concentration (reading at 260 nm wavelength) and the purity (reading at 280 nm 
wavelength) of the DNA. Once the DNA concentration was measured, each sample was 
normalized to a concentration of 10 ng/μl. 
 
2.3  Experimental design 
The Ion AmpliSeqTM Designer is a free and available online tool created for Ion Torrent 
users. By entering the chromosomal coordinates and the name of the target genes, the 
software provides a primer list divided in two primer tubes for multiplex-PCR amplification 
(for panel size up to 50 genes). All theoretical data related to the quality are also provided 
by the design. At the beginning of PhD project, the first design has been created including 
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the four genes involved in PFIC: ATP8B1, ABCB11, ABCB4 and TJP2. The design was 
conceived to cover the entire coding region of the four genes and 50 base pairs flanking the 
beginning and end of each exon, to be able to identify also intronic variants potentially 
implicated in the splicing process. A real coverage of 99% was obtained with 194 amplicons 
for a total panel size of 42 kb. With this four-genes panel we analysed 96 patients. 
In the second year of the project we decided to expand our gene panel because of new genes 
probably associated to the disease by the literature. In scientific literature we found a 
considerable quantitative and qualitative diversity of genetic panels analysed between the 
different groups and the data were quite conflicting. Therefore, considering also the clinical 
and phenotypic data of our patient pool we decided to include other eleven genes with a 
biological rationale: 
the ABCC2 gene, coding for a protein member of the superfamily of ATP-binding cassette 
(ABC) transporters and expressed in the canalicular (apical) part of the hepatocyte and 
functions in biliary transport. Several different mutations in this gene have been observed 
in patients with Dubin-Johnson syndrome (DJS), an autosomal recessive disorder 
characterized by conjugated hyperbilirubinemia. The CLDN1 gene, which encodes the 
Claudin-1 protein, is part of the tight junction complex and causes sclerosing-neonatal 
ichthyosis (NISCH syndrome); GPBAR1, which codes for the G Protein-Coupled Bile Acid 
Receptor 1, a cell membrane receptor for bile acids associated with sclerosing cholangitis; 
NR1H4, associated with progressive familial intrahepatic cholestasis 5 (PFIC5, ¶ 1.3.5); 
JAG1, (involved in Notch signalling) and NOTCH2 (Jagged-1 protein receptor) whose 
mutations cause Alagille syndrome; MYO5B, associated with Myo5b-Related PFIC (¶ 1.3.6); 
SLC25A13, associated with citrullinemia; SLCO1B1 and SLCO1B3 (Solute Carrier Organic 
Anion Transporter Family, associated with hyperbilirubinemia and ICP; VPS33B associated 
with PFIC1 phenotype. 
The new panel included (and still includes today) 15 genes: ATP8B1, ABCB11, ABCB4, TJP2, 
NR1H4, MYO5B, JAG1, ABCC2, NOTCH2, CLDN1, GPBAR1, SLC25A13, SLCO1B1, 
SLCO1B3 and VPS33B, for a total of 436 amplicons and 85 kb, with a total coverage of 99.9% 
of the target.  Considering the new panel size we had to upgrade the equipment used, in 
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this regard we started to use Ion S5 GeneStudio (Thermo Fisher Scientific, Waltham, MA, 
USA), available for sharing with the departments of Pathological Anatomy and Medical 
Genetics of the Sant'Orsola-Malpighi Hospital (¶ 2.10). 
 
2.4 Workflow 
2.4.1 Library construction 
Libraries were prepared using the recommended Ion AmpliSeqTM Library Kit 2.0 (Thermo 
Fisher Scientific, Waltham, MA, USA) which includes a five-step structured workflow: 
 
2.4.1.1 Amplification 
The amplification step was performed by setting up a multiplex-PCR. The reaction mix and 
amplification conditions are shown in the tables below and are intended for single sample, 
amplified for each pool. 
 
 
Reagents Volume (µl) 
5X Ion AmpliSeqTM HiFi Master Mix 2 
2X Ion AmpliSeqTM Primer Pool 5 
gDNA (10 ng) 1 
Nuclease-free H2O  2 
Final volume 10 
 
Temperature Time Cycles 
99 °C 2′ 1 
99 °C 15′′ 
19 
60 °C 4′ 
10 °C Hold End 
 
 
2.4.1.2 Primer digestion 
Following amplification, 1 µl of FuPa Reagent was added to each sample, allowing partial 
digestion of primers and phosphorylation of amplicons. Samples were then incubated in 






50 °C 10’ 
55 °C 10’ 
60 °C 20’ 
10 °C Hold* 
* for up to 1 hour 
 
2.4.1.3 Adapters and barcode binding and purification 
In this step the reaction mix shown in the table below was added to each sample, amplified 
with both pools, and samples were incubated in thermal cycler, according to the described 
conditions. 
 
Reagents Volume (µl) 
Switch solution 2 
Ion P1 adapter 1 
Ion XpressTM barcode 1 
DNA ligase 1 
Nuclease-free H2O  1 




22 °C 30′ 
72 °C 10′ 
10 °C Hold* 
* for up to 1 hour 
 
 
For purification phase, special magnetic spheres that select fragments greater than 100 bp 
have been used. The processed samples were transferred into a 1.5 ml Eppendorf, 
resuspended with Agencourt AMPure XP Reagent 1.8X and incubated at room temperature 
for 5 minutes. After incubation, the Eppendorf were placed in the special DynaMagTM 2 
magnetic rack (figure 11) for about 3 minutes. In this way, the magnetic beads that have 
bound the 175-275 bp fragments are arranged along the wall of the Eppendorf, allowing the 
removal of the supernatant. Subsequently, three washes were carried out with 70% ethanol 
(freshly prepared). The Eppendorf were removed from magnetic rack, pellet was 
resuspended in 25 µl of Low TE and incubated at room temperature for about two minutes, 
to allow the fragments to detach from beads. Finally, the Eppendorf were again placed in 
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the magnetic rack and the supernatant, this time containing only the fragments of interest, 




Figure 11. Magnetic rack. On the left DynaMag-2 Magnet compatible with 1.5 
ml Eppendorf. On the right DynaMag -96 Side Magnet, compatible with 0.2 ml 
micro-tube, in strip or singles (Thermo Fisher Scientific, Waltham, MA, USA). 
 
 
2.4.1.4 Library quantitation 
Libraries obtained from previous steps were quantified by Real Time-PCR. The quantitation 
was carried out using the Ion Library TaqManTM Quantitation Kit (Applied Biosystems by 
Thermo Fisher Scientific, Waltham, MA, USA). The assay allows to obtain a quantity 
measurement of fragments to which adapters have been bound. This is possible because of 
marked probes are complementary to their sequences. For this purpose, serial dilutions of 
a known stock concentration (68pM) of control library, E. coli DH10B Ion Control Library 
(6.8 pM, 0.68 pM, 0.068 pM and 0.0068 pM), have been prepared. This step is fundamental 
in order to construct a calibration curve on which the concentrations of libraries are 
determined (previously diluted 1:500). For qRT-PCR assay, the reaction mix reported in the 
following table was used and samples were incubated in the StepOneTM Real-Time PCR 




Reagents Volume (µl) 
2X Ion TaqManTM Master Mix 5 
20X Ion TaqManTM Assay 0.5 
Samples* Volume (µl) 
E. coli serial dilutions 4.5 
Diluted library (1:500) 4.5 
Final volume for each sample 10 
* 8 wells for 4 E. coli different concentrations and 
x*2 wells for x samples (each in double)  
 
Temperature Time Cycles 
50 °C 2′ Hold 
95 °C 20′′ Hold 
95 °C 1′′ 
40** 
60 °C 20′′ 
** at last cycle real time will 
automatically end 
 
2.4.2 Library pooling 
After quantitation, libraries of both pools were combined into a single 0.2 ml reaction tube 
at equimolar concentration (9 pM). 
 
2.4.3 Template preparation 
2.4.3.1 Emulsion PCR 
For this step the Ion PGMTM Hi-QTM View OT2 kit (Thermo Fisher Scientific, Waltham, MA, 
USA) was used. The preparation of template was performed using emulsion-PCR 
technique. Pool fragments of all libraries have been mixed with an excess of spheres (Ion 
SphereTM Particles), so that each amplicon binds to the surface of a sphere. The library 
dilution therefore represents the key step to avoid, or at least minimize, the production of 
polyclonal spheres. 
The emulsion was created by properly mixing the PCR reagents (shown in the table below) 
with mineral oil, in a special reaction filter. The filter was immediately loaded on the Ion 
OneTouchTM 2 System instrument (Thermo Fisher Scientific, Waltham, MA, USA) (figure 
12), which contains a heating block with the amplification plate inserted in and produces a 
temperature gradient from 95 ° C to 64 ° C. The plate contains a channel that allows the 
reaction mix to move and allows the temperature changes needed for the reaction. 
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To a 2-mL tube containing 800 μL of Ion PGM™ Hi-Q™ 
View Reagent Mix, add the following components in the 
designated order: 
Reagents Volume (µl) 
Nuclease-free H2O  25 
Ion PGMTM Hi-QTM View Enzyme Mix 50 
Diluted library 25 
Ion PGMTM Hi-QTM View ISPs 100 
Final volume 1000 
 
Figura 12. Ion OneTouchTM 2 System. 
(Thermo Fisher Scientific, Waltham, MA, 
USA). 
  
2.4.3.2 Quality control 
The quality control of emu-PCR is carried out with the Ion SphereTM Quality Control Kit, 
which involves two fluorochromes: one binds the spheres (Alexa Fluor 488 dye) and the 
other binds the external adapter (Alexa Fluor 647 dye), therefore binding together the 
template. Samples are prepared in special 0.2 ml tubes and incubated in the thermocycler 
under the reported conditions. 
 
Reagents Volume (µl) 
Annealing Buffer 19 
Ion ProbeTM 1 
Unenriched sample 2 




95 °C 2′ 




The enrichment of the emulsion-PCR product allows the selection of the spheres that have 
bound the template and the removal of the empty spheres but does not allow to exclude the 
polyclonal ones. This phase exploits the action of streptavidin, which recognizes and binds 
the amplicon bound to the sphere. In this step, the Ion PGM™ Enrichment Beads kit and the 
Ion OneTouchTM ES instrument were used to automate the process. The instrument uses a 





Figure 13. Ion OneTouchTM System.  On the left strip preparation (numbers in the list correspond to the 
number of the strip well). B. strip into the Ion OneTouch ES (Ion PGM™ Hi‐Q™ OT2 Kit Quick Reference). 
 
2.5 Chip loading 
Final sample is released into a 0.2 ml tube, previously placed in a special housing in the 
OneTouchTM ES. Five microliters of Control ISPs from Ion PGMTM Hi‐QTM View Sequencing 
Kit were added. The sample was centrifuged at 15500 rpm for 2 minutes and the supernatant 
was removed. Subsequently, 12 µl of Sequencing Primer are added and the tube is incubated 






Temperature Time Cycles 
95 °C 2′ 1 
37 °C 2′ 1 
 
The thermal-cycler incubation allows the annealing of sequencing primers to the template 
attached to the spheres. After incubation, 3 μL of Ion PGM™ Hi‐Q™ View Sequencing 
Polymerase was added to the sample. 
Several sequencing sessions were performed for this project. At the beginning of the project 
we used Chip 318 v.2 and Ion Torrent PGM sequencer; later (see below) we used Ion 
GeneStudio S5 and Ion Chef. By the Pipet-Lite XLS+ pipette, enriched pool was inserted 
inside the chip (through the loading port) carefully, avoiding the introduction of bubbles. 
The chip was later inserted in a special mini centrifuge for 30 seconds. After, the chip is 
tilted by 45° and the liquid inside was resuspended. The subsequent centrifuges allow the 
spheres that have bound the template and the polymerase to settle inside the chip’s micro-
wells. These last steps were repeated 3 times. After the third centrifugation, the liquid is 
removed entirely from the chip and was loaded into the Ion Torrent PGMTM sequencer 
(figure 14). 
    A     B 
 
 
Figure 14. A. Chip loading. B. Ion-Torrent PGM sequencer. A) touch screen control, B) Ion-chip loading 
deck clamping mechanism, C) special material grounding plate, D) power button, E) Reagent bottles, F) Wash 





After about half an hour from the beginning of the sequencing, a preliminary Run Report is 
available (figure 15). The report shows some details about the chip loading, the ISPs and 
reads quality. In the first box, at the top left, there is a photo of the chip loading, with the 
total number of bases produced (1.06 G in this case) and the percentage of micro-wells 
containing a live ISP with template attached (figure 15a). In the central box, at the top, the 
total number of reads, the percentage of empty wells and the percentage of wells that 
contain an ISP with bounded template (enrichment = 100%) are described. The 67% of clonal 
spheres indicates the spheres that have tied a clone coming from a single template, so they 
possess sequences that has the same origin of one template; the remaining 33% indicate the 
polyclonal spheres. In the box at the top right mean, median, mode and read length graph 





   A 
 
   B 
 
 
Figure 15. Run report from one of our sequencing runs. A. Summary report in PDF, downloaded from Ion Torrent 
server (see text for details). B. Samples details. Output file showing barcode name, sample name, bases sequenced, 
reads exceeding quality Q20 cut-off, number and mean of the reads and a length graph.  
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2.6 NGS data analysis 
Ion PGMTM Sequencer transfers row sequencing data to the Torrent Server, which converts 
raw data to base calls and the Torrent SuiteTM generates the summary sequencing report and 
Fastq files. Reads are aligned to human genome (hg19 version) and Binary Alignment Map 
(BAM) in conjunction with Binary Alignment Index (BAI) and Variant Call Format (VCF) 
files are produced.  
It is possible to visualize reads aligned of BAM/BAI files using Integrative Genome Viewer 
(IGV) Software. IGV is currently used to assess the coverage depth of the sequencing reads, 
zygosity, quality of the sequencing reads and mapping quality.  
All the VCF files are uploaded into the Ion Reporter software 
(https://ionreporter.thermofisher.com/ir/), selecting the Annotation Variant workflow in 
order to associate each variant identified to the nucleotide change in cDNA and mRNA 
transcript, the aminoacidic change, the exons or IVS and its function. Moreover, the Ion 
Reporter can readily access to several prediction programs used to evaluating the 
pathogenic potential of missense change, providing important information about the 
pathogenicity of the variants analysed (buying license).  
 
2.6.1 Variant filtering strategy 
The read files obtained from sequencing were mapped to the GRCh37/hg19 assembly and 
the sequence variants were identified by Variant Caller and Ion Reporter software.  
The filtering step of sequence variants was carried out according to default criteria for 
germline mutations: insertions or deletions, non-sense variants, splicing-site variants, and 
missense with minor allele frequency (MAF) ≤ 0.05 were considered. Three bioinformatics 
tools were used to predict the role of missense variants. Sorting Intolerant From Tolerant 
(SIFT) (http://www.jcvi.org/cms/home/), PolyPhen-2 and Mutation Taster software can 
evaluate whether an amino-acid substitution influences protein structure and function, 
according to physical modifications and the degree of conservation of protein sequence 
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among species. Variants that meet at least one of the following criteria were also considered: 
ever described before, reported in Human Gene Mutation Database (HGMD®), predicted 
not benign by at least one of the bioinformatic tools. 
All the variant found were classified following The American College of Medical Genetics 
and Genomics 2015 (Richards et al. 90) in five principal categories: 
 
1. Pathogenic (P): all the Loss of Function (LOF) mutations as nonsense, frameshift, 
indel non-frameshift, canonical splicing variants, and the SNP occurring into the 
ATG starting codon; 
2. Likely Pathogenic (LP): all the missense described as pathogenic variants listed in 
HGMD® (Human Gene Mutation Database). Novel missense variants with a Minor 
Allele Frequency (MAF) < 0,01 on free online databases like gnomAD (Genome 
Aggregation Database, https://gnomad.broadinstitute.org/), predicted as damaging 
or not tolerated by main bioinformatic tools as PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT sequence (Sort Intolerant From 
Tolerant) (https://sift.bii.a-star.edu.sg/www/SIFT_seq_submit2.html); 
3. Variant of Uncertain Significance (VUS): all novel missense rare variants with 
discordant prediction results or where poor data are available. 
4. Likely Benign (LB): all frequent missense variants and rare synonymous and 
intronic (near the canonical splicing site) variants predicted to not affect function by 
Human Splicing finder (http://www.umd.be/HSF3/); 
5. Benign (B): all the deep intronic variants and frequent synonyms variant in non-
conserved sequence domains. 
 
Variants passing the above filtering process were mapped to Uniprot canonical sequences 
and subjected to Mechismo analysis to predict their functional consequences at 
biomolecular interaction interfaces. The approach matches protein sequence aminoacids to 
positions within structures and identifies sites affecting interactions with other proteins, 
DNA/RNA or small molecules. We considered low confidence predictions including known 
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structures or close (C 30% sequence identity) homologs and only very confident, physical 
protein–protein interactions (as defined by Mechismo based on a benchmark for the 
accuracy of perturbed interfaces). 
We annotated mutations and PTMs (phosphorylations and acetylations) from Phosphosite 
(https://www.phosphosite.org/homeAction.action) of the considered genes on 
corresponding Uniprot canonical sequences using lollipop diagrams. 
 
2.7 Statistical analysis 
Categorical and quantitative variables were used to perform statistical analysis. 
Quantitative variables were Body mass index (BMI), level of liver fibrosis (based on 
Fibroscan® scores), laboratory features like alkaline phosphatase (AP), γ-
glutamyltransferase (GGT), aspartate and alanine aminotransferases (AST and ALT), total 
and direct bilirubin and albumin levels. Presence of P/LP mutations and number of variants 
per patient were also considered variables. 
Continuous variables were also categorized according to established pathological cut-offs. 
For each continuous parameter the normality of the distribution was checked by the 
Kolmogorov-Smirnov and Shapiro-Wilk tests, then parametric or non-parametric test were 
used accordingly to assess differences between genotypes. 
Contingency tables were developed by matrices of frequency distribution of the variables 
and used to compare categorical variables. while for quantitative variables the one-way 
analysis of variance (ANOVA) was used. 
Binary logistic regression was performed for univariate analysis to identify alleles with 
potential risk factors. A p < 0.05 was considered significant for all tests.  
About non-parametric tests, independent samples Mann-Whitney U (2 samples) test and 
Kruskal-Wallis one-way ANOVA (k samples) test were performed. 




Allele frequency (AF) of common single-nucleotide polymorphisms (SNPs) was matched 
with data reported in the 1000 Genomes Browser and compared with TSI population 
(Toscani in Italy) (https://www.internationalgenome.org/1000-genomes-browsers/) by 
using de Finetti test. This analysis is part of the case-control studies and tests the deviation 
from the Hardy-Weinberg principle (HWP) performing Pearson's Chi-squared test by using 
the observed genotype frequencies obtained from the data and the expected genotype 
frequencies obtained using the HWP. The output of the de Finetti test shows also the allele 
and genotype associations with the disease, comparing alleles and genotypes frequency 
between controls and patients 91, as shown in the table 4. Still, a p < 0.05 was considered 
statistically significant in this analysis. 
 
Table 4. The de Finetti output. HW equilibrium and association for SLCO1B3 c.699G>A (p.M233I), 
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2.8 Validation of NGS data by Sanger sequencing 
Sanger sequencing was performed in order to validate all the variants classified as 
pathogenic, likely pathogenic and VUS. Primers have been designed for each of these 
variants. After amplification in thermal cycler, sequencing of purified amplicons was 
performed by ABI Prism 3730 DNA Analyzer (Applied Biosystem, Foster City, CA, USA), 




Reaction mix Volume (µl) 
Nuclease-free H2O 4 
Big-DyeTM Buffer (5X) 2 
Big-DyeTM Terminator 3.1 1 
Primers (3,2 pmol/µl) 1 
Purified template 2 
Final volume 10 
 
Temperature  Time Cycles 
96 °C 30′′ 1 
96 °C 10′ 
25 
60 °C 3′ 
10 °C 4 Hold 
 
N.B. Mix and thermal cycler conditions for Sanger sequencing reaction. Previous amplification 
conditions are not shown, due to different and specific condition of each genomic segment in which 
variants has been identified. 
 
2.9 MLPA analysis 
MLPA® (Multiplex Ligation-dependent Probe Amplification, MRC-Holland, Amsterdam, 
NL) is a multiplex PCR method detecting large genomic rearrangement and copy number 
variations (CNVs). Commercial kit containing specific probe for one gene analysis are 
available by this company. This technique is not suitable for all genes. Thus, we have kit for 
the ABCB4 analysis. Patients resulting wild type to NGS test and carrying typical PFIC3 
phenotypes were choose by physicians for MLPA test. MLPA for ABCB4 gene was 
performed by Salsa® MLPA® P109 ABCB4 probe mix. 
The protocols consist of three different steps (not shown). 
 
2.10  Ion GeneStudio S5 system 
As soon as we started to perform new NGS-panel analysis with 15 genes (and a target region 
of 85 kb), we decided to upgrade it. So, when new equipment was available, we started to 
use the Ion S5 GeneStudioTM System (Thermo Fisher Scientific, Waltham, MA, USA), 
available for sharing with the departments of Pathological Anatomy and Medical Genetics 
of the Sant'Orsola-Malpighi Hospital.  
The Ion GeneStudioTM S5 System is a semiconductor-based next-generation sequencing 
(NGS) system that enables simple targeted sequencing workflows exploiting the same 
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theory of its older relative PGM, but it is more efficient (figure 16a). The differences with 
Ion PGM are: high throughput to achieve from 2 to 80 million reads per run; reduce setup 
time and complexity with cartridge-based plug-and-play reagents; reduced time to 
complete run and analysis. A new chip series has been developed by the company to better 
fit with this instrument and to increment the number of reads produced per run. This 
evolution let us to analyse more samples in less time. 
In the last six months we started to use the Ion Chef™ Instrument. The Ion Chef System is 
the next generation of workflow simplification products for the Ion GeneStudioTM S5 
Systems. The Ion Chef System provides automated library preparation, template 
preparation, and chip loading. In less than 1 hour of up-front hands-on time and with the 
use of pre-packaged library preparation reagent kits, the Ion Chef System provides a 
convenient walk-away workflow resulting in equalized, pooled libraries ready for 
templating and producing one or two chips ready for sequencing (figure 16b). We realize 
that the better way to use the Ion Chef was from template preparation to the end, continuing 














3.1  Assay analysis 
The Next-Generation Sequencing technology, characterized by high throughput and 
convenient benchtop workflows, was used to develop a rapid and cost-effective molecular 
diagnostic method for PFIC. 
The NGS platform used in this work was the Ion Torrent Personal Genome MachineTM 
(PGM) for the first two years of the project and Ion GeneStudioTM S5 for the last one (Thermo 
Fisher Scientific, Waltham, MA, USA), two highly suitable instruments for targeted-
resequencing assay for DNA, RNA and small genomes.  
For the purpose of this study Ion AmpliseqTM technology for the target-resequencing was 
developed. Through the Ion Ampliseq DesignerTM software we designed two different NGS 
panels, as mentioned above (¶ 2.3): the four-gene panel with ATP8B1, ABCB11, ABCB4 and 
TJP2, for 194 overlapping amplicons and a target regions of about 48 kb (IAD61312_182); 
the fifteen-gene panel, including ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, MYO5B, JAG1, 
ABCC2, NOTCH2, CLDN1, GPBAR1, SLC25A13, SLCO1B1, SLCO1B3 and VPS33B, for a total 
of 436 amplicons and 85 kb, with a coverage of 99.9% of the target (IAD142012_1000) (table 
5, figure 17). Those two panels characterized by overlapping amplicons divided in two 
pools each were used to allow us to achieve ultra-high multiplexing-PCR for the complete 
coverage of the entire coding sequences, i.e. exons and their flanking regions. 
As regard the fifteen-gene panel, all the missed regions (74 bp in exon 2 of NOTCH2, 25 bp 
in exon 18 of SLCO1B1 and 1 bp in exon 20 of VPS33B) were investigated by Sanger 
sequencing.  
The library barcoding allowed the simultaneous sequencing of more patients per run. 
Despite the remarkable dimension of the fifteen-gene panel target region, an average 
coverage of about 1000X was obtained for the simultaneous sequencing of 15 patients on a 
520 chip by Ion S5. For the four-genes panel an average coverage of over 800X was obtained 
submitting 12/14 patients in a single run on Ion PGM 318 chip.  
The two NGS panels resulted both reliable in detecting variants, let us capable of obtain the 
same detection rate of other research groups. It is also true that Ion GeneStudio S5 was more 
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efficient than Ion PGM, resulting in an easier workflow with less probability to induce the 
operator into errors. 
 
 








Figure 17. Integrative Genomics Viewer (IGV) of NOTCH2 gene. Genomic region (158 kb, on the top) of NOTCH2 
gene visualized on IGV through Ion AmpliseqTM Designer tool. From the top to the bottom: yellow segments show the 
theoretical coverage under standard conditions; green segments show amplicons produced by the tool sometimes 
overlapping; in this gene there are no missed region; blue line indicates genomic space of the gene and vertical segments 
represent exons (www.ampliseq.com). 
 
3.2  Results from four-gene panel analysis 
Of the 96 patients sequenced with the four-gene panel, we had clinical and laboratory 
information for 48 of them. Chronic idiopathic cholestasis was defined as GGT e/o alkaline 
phosphatase persistently ≥ 1.5-fold the upper normal values in at least two tests or as history 
of itching combined with elevated serum bile acids concentration (10 μmol/l) for more than 
6 months. PFIC patients underwent laboratory analysis, including bile acids serum 
concentration, liver fibrosis evaluation by transient elastography (Fibroscan®) and, if 
indicated, liver biopsy within 6 months from the execution of the genetic tests. 
Comprehensive molecular analysis of ABCB11, ATP8B1, ABCB4 and TJP2 genes was 
performed by Ion Torrent PGM (Thermo Fisher Scientific, Waltham, MA, USA). Molecular 
analysis was simultaneously carried out in 12 barcoded samples in an Ion 318 v2 Chip for 
each run. We used our variation filtering strategy according to ACMG standards (¶ 2.6.1), 
patients’ phenotypes and their familial history. 
In table 6 are shown the main features of our cohort. A history of familial cholestatic 
diseases and DIC was present in 35%, itching in 27%, neonatal jaundice in 21%, juvenile 
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cholelithiasis in 17%, personal or family history of ICP in 13%. Histologic features of 
cholestasis were present in 65% of cases (overall 44 patients agreed to a liver biopsy). 
 
 
Table 6. Schematic representation of age, time, risk factors and laboratory variables of 
our cohort. N: number, SD: standard deviation, DIC: drug-induced cholestasis, ICP: 
intrahepatic cholestasis of pregnancy, GGT: gamma-glutamyltransferase, AP: alkaline 




Gene analysis revealed the presence of P/LP mutations in about one-fourth of subjects; 
clinical features and type of mutations found in the 12 patients (eleven unrelated probands 
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Table 7. Patients with P/LP mutations identified in the four-gene panel. ID 4 and 4a are affected sibling. Sequence variants 
are reported according to HGVS recommendations (http://varnomen.hgvs.org). 
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3.2.1 ATP8B1 variants 
Five variants were identified in the coding region of ATP8B1. According to ACMG 
standards, two variants were labelled as LP: c.3655G>C (p.D1219H) in exon 28 and c.68C>T 
(p.P23L) in exon 2; the first was combined with heterozygous TJP2 LP mutation c.1057C>T 
in a 71-year-old woman (case 1 in table 7) with a long history of cholestasis, 5.5 kPa at 
Fibroscan (F1). The second is a novel mutation found in a 31-year-old male (case 2 in table 
7) who experienced neonatal jaundice and juvenile cholelithiasis, with low GGT, 7.4 kPa at 
Fibroscan (F2) and having also LB variants in ABCB11.  
We classified the missense c.134A>C (p.N45T) in exon 2 and c.607A>G (p.K203E) in exon 7 
as VUS and each was previously described as risk allele in ICP (CM051009 and CM051010, 
Painter et al. 2005) 68. We found these variants in compound heterozygous in a 36-year-old 
female who showed a cholestatic disease characterized by normal GGT and high bile acids 
levels, neonatal jaundice, juvenile cholelithiasis complicated by LPAC, and a history of ICP. 
We found the N45T three times (two with this panel and one with 15-gene panel) and the 
K203E two times. The second patient having the N45T is a 60-year-old woman having also 
three LB variants in ABCB11, ABCB4 and TJP2. 
The second patient carrying the K203E is a 71-year-old woman with a late onset. 
We found one B/LB variant: the c.2855G>A (p.R952Q) in exon 23. The SNP p.R952Q was 
found in five cases and in two patients was combined with LP mutations, one on ABCB11 
and one on TJP2, respectively. Allele frequency of p.R952Q was significantly higher in 
comparison with the one of East Asian population (10.4 vs. 0.03%: p < 0.0001) and 
comparable with European and worldwide data (table 8). 
Variants’ analysis and structural annotations on available crystalized structures or 
homology models from PDB (Protein Data Bank, www.rcsb.org) revealed that two variants, 
i.e., p.K203E and p.F305I are found in spatial proximity within the ATPase catalytic domain 
(figure 18), suggesting potential converging effect on the enzymatic activity, while the 
p.R952Q is found at the transmembrane (i.e., phospholipid translocating) domain. The LP 
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variants P23L and D1219H, reside at the N- and C-terminals of the protein, outside the 
structured portion (figure 21 page 77). 
 
 
Figure 18. ATP8B1 lollipops. Protein sequence annotations of PFIC1 non-synonymous mutations displayed as pink and 
red lollipops to indicate respectively B/LB or VUS and P/LP predicted consequences. Circle diameters are proportional 
to the number of patients affected. Blue and green lollipops indicate phosphorylation and acetylation sites. Protein 
sequence regions corresponding to conserved domains are highlighted by colored boxes and are indicated by their 
respective Pfam names. 
 
3.2.2 ABCB11 variants 
Eleven variants were identified in the coding region of ABCB11 and seven resulted as P/LP 
mutations. Three causative mutations, c.278A>C (p.Y93S) in exon 5, c.1789G>C (p.V597L) in 
exon 15 and c.3382C>T (p.R1128C) in exon 25 were combined in a young female (29 years) 
presenting with a history of neonatal jaundice, DIC, ICP, juvenile cholelithiasis, itching, 
normal GGT and high bilirubin levels (case 3 in table 7). Fibroscan analysis revealed a score 
of 12 kPa (F3). 
Two sisters (20 and 7 years) were carriers of the LP homozygous mutation c.1568C>G 
(p.A523G) 92 in exon 14: both had history of neonatal jaundice, itching and DIC (cases 4 - 4a 
in Table 7), but there were differences at Fibroscan analysis (20.9, F4 vs 10.1 kPa, F3). Last 
two P/LP mutations, c.3297delC (p.S1100Qfs*38) in exon 25 and c.403G>A (p.E135K) in exon 
6, were responsible for a double heterozygosis in a boy with history of itching and neonatal 
jaundice, 11.5 kPa (F3) at Fibroscan and listed for liver transplantation (case 5 in table 7).  
The disease-causing mutation c.2494C>T (p.R832C) in exon 21 was previously reported in 
HGMD (CM067617) as PFIC2-causing mutation by Walkowiak et al. 2006. We found it in a 
40-year-old female who had normal GGT and undergone liver transplantation at age of 
sixteen due to Byler’s disease, and no information about familial lineage were present. The 
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patient had also the novel VUS (private variant) c.833G>A (p.G278E) in exon 9 of ABCB11, 
another VUS in ABCB4 and the LB variant R952Q in ATP8B1 (case 6 in table 7). 
Multiple lines of computational evidence support a deleterious effect on the gene or gene 
product by the G278E (13 pathogenic predictions from DANN, DEOGEN2, FATHMM, 
FATHMM-MKL, FATHMM-XF, LRT, M-CAP, MutationAssessor, MutationTaster, 
PROVEAN, PrimateAI, SIFT and SIFT4G vs no benign predictions), it is not present in 
ClinVar and for VarSome it is considered as VUS, due to poor information. 
Another VUS was the novel variant c.209T>C (p.F70S) in exon 5. 
The c.1268A>G (p.H423R) in exon 12 is a rare variant (MAF: 0.0002) predicted to be tolerated 
(0.53) by SIFT and probably damaging (1.000) by PolyPhen (discordant predictions by the 
two tools) and it was identified in a 48-years-old female with elevated GGT, carrying also 2 
LB variants in ABCB11 and ATP8B1. MLPA analysis for large genomic rearrangements of 
ABCB4 gene was also performed on patient’s DNA, resulting negative. 
Benign mutations detected were among those previously described 74: c.2029A>G (p.M677V) 
in exon 17, detected in nine patients, and c.1331T>C (p.V444A) in exon 13, found in 40 cases 
(83.3% of population studied). Of note, SNP c.1331T>C was reported associated to DIC and 
ICP in previous reports 74 and recently to cholestatic phenotype in patients without disease-
causing mutations in the respective gene. Allele frequency of p.V444A was significantly 
more frequent in our cohort of patients without P/LP mutations in comparison with 
European and worldwide populations (81 vs. 60%: p = 0.008; 81 vs. 57%: p = 0.002). We also 
observed a higher allele frequency of p.M677V in our cohort with and without P/LP 
mutations respect to all other populations (13.5 vs. 1.76% European, 0% East Asian, 2.7% 
worldwide: all p < 0.0001) (table 8). 
All nine reported mutations for ABCB11 were mapped to homolog available structures from 
PDB through Mechismo (figure 19). P/LP variants were found to be located either at ATP-
binding domain, like p.A523G, p.V597L, p.S1100Qfs*38 and p.R1128C, or at transmembrane 
domain, like p.E135K or p.Y93S, which are also found in spatial proximity (figure 20 page 
77). Moreover, the variant p.H423R was found at the interface with the ATP-binding pocket. 
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This overall suggests that deleterious mutations on ABCB11 might similarly affect the ATP-
binding cassette (ABC) transporter’s functionality by impairing ABC catalytic activity, or by 




Table 8. Allele frequencies of detected SNPs. The allele frequencies (AF) of common single-nucleotide polymorphisms 
(SNPs) in ATP8B1, ABCB11, ABCB4 and TJP2, in the full cohort (a) of patients with and without (w/o) pathogenic/likely 
pathogenic (P/LP) mutations (b) were compared to AF available from the Genome Aggregation Database (gnomAD) 
either of the non-Finnish European population (1), East Asian population (2), and worldwide population (3) (gnomAD: 
http://gnomad.broadinstitute.org/). p values were calculated using the Chi-square test by GraphPad web software 
(https://www.graphpad.com/quickcalcs/contingency1.cfm). p < 0.05 are in bold (Vitale et al. J Gastroenterol. 2018). 
 
3.2.3 ABCB4 Variants 
We identified seven variants in the coding region of ABCB4 and four were P/LP mutations.  
The mutation c.1208A>G p.Y403C was a novel variant. It is located in the same position of a 
mutation previously described by Degiorgio 93 Y403H (CM075960 on HGMD) as associated 
to PFIC phenotype. For this reason, we can assess that this aminoacid residue is a mutational 
74 
 
hotspot, so the probability that the variant is pathogenic is very high. We found this 
mutation in a 42-year-old female (case 7 in table 7) with history of ICP, LPAC and juvenile 
cholelithiasis. The same variant was found in his affected brother. Only the man had also a 
LB variant in ABCB4.  
The c.2014A>T (p.K672*) in exon 16, previously undescribed, was found in a 39-year-old 
woman (case 8 in table 7) with familiarity for cholestatic diseases and cholelithiasis 
(mutation was inherited from the affected father), history of DIC and itching, with high GGT 
and a Fibroscan score of 7.7 kPa (F2). 
The c.1091C>T (p.A364V) in exon 10, described by Degiorgio et al. 93, was present in a 57-
year-old cirrhotic patient with high AP and GGT, 35.8 kPa at Fibroscan (F4), DIC and 
hepatocellular carcinoma (case 9 in table 7). 
The c.2324C>T (p.T775M) seemed to be a VUS and found in a 41-year-old male with a 
mutation in TJP2 (I906T). Sanger sequencing confirmed these two mutations to segregates 
in the affected brother (31 years). For this reason, we reclassified the T775M as LP mutation.  
Three VUS, p.L73V (c.217C>G) in exon 4, c.523A>G (p.T175A) in exon 5 and c.2324C>T 
(p.T775M) in exon 19 were identified, previously associated to different PFIC3 phenotypes. 
The c.523A>G (p.T175A) was seen two times in our cohort (4- and 15-gene panel). 
The missense variant p.T775M was detected together with LP c.2717T>C (p.I906T) in exon 
18 of TJP2 in a 37-year-old male presenting a familiarity for cholestasis (case 11 in table 7), 
while the variant p.L73V was detected in a 23-year-old female with high GGT levels, 
without evidence of significant liver fibrosis at Fibroscan.  
The known LB variants c.711A>T (p.I237=) in exon 8 and c.1954A>G (p.R652G) in exon 16 
were found in 16 and four cases, respectively. The SNP p.I237= was associated in previous 
reports with elevated GGT-cholestasis, ICP, and gallstones 56. 
Allele frequency of p.I237= was significantly more common in our cohort of patients with 
disease-causing mutations than in European and worldwide population (33 vs. 18%: p = 
0.004; 33 vs. 21%: p = 0.033; table 8). Frequency of p.R652G was similar between our cohort 
and both European and worldwide population. 
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ABCB4 non-synonymous mutations, with exception of the stop-gain p.L672*, were mapped 
to the same available homolog structure used for ABCB11 but revealed no defined patterns 
(figure 19). Mutations were essentially located in intrinsically disordered regions (figure 21 
page 77).  
Among our cohort, physicians selected 21 patients with a phenotype attributable to ABCB4 
gene. Thus, ABCB4 MLPA analysis was performed and only one patient had a heterozygous 




Figure 19. ABCB11 and ABCB4 lollipops. Legend is the same of the Figure 18 (ATP8B1). ABCB11 and ABCB4 have the 
same Pfam domains, as they are both ATP-binding cassette sub-family B members.  
 
3.2.4 TJP2 variants 
Variants identified in the coding region of TJP2 were thirteen: three LP mutations, one VUS, 
and nine B/LB variants. 
Among LP mutations, the c.278C>T (p.T93M) in exon 3 was found in two unrelated cases 
(case 10 in table 7), one who experienced DIC and ICP. 
The c.1057C>T (p.R353W) in exon 6, combined to LP heterozygous p.D1219H on ATP8B1 in 
a 71-year-old man presenting only high GGT (case 1), and c.2717T>C (p.I906T) in exon 18 
associated with LP p.T775M in ABCB4 in one patient with familiarity for cholestatic diseases 
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(case 11 in table 7). Differently from what has been reported in a previous report 19, all three 
patients presented high GGT.  
The only VUS identified was the c.46A>G (p.K16E) in exon 1. B/LB mutations were c.43G>C 
(p.V15L) and c.71G>A (p.R24H) in exon 1, c.475C>A (p.Q159K) and c.860C>T (p.A287V) in 
exon 5 (in two unrelated probands), c.1571G>A (p.R524K) in 3 unrelated probands in exon 
10, c.1686C>T (p.Val562=) in exon 11, c.2097G>A (p.M699I) and c.2224T>C (p.S742P) in exon 
14 and c.3465G>A (p.T1155=) in exon 22. 
VUS p.K16E was present in a 31-year-old female associated to benign c.1954A>G and 
c.711A>T mutations in ABCB4: the patient had a history of ICP, juvenile cholelithiasis and 
recurrent DIC to different drugs used for multiple sclerosis. Finally, a 31-year-old man with 
high GGT and bile acids levels presented the LB variant V15L. 
Most deleterious TJP2 mutations were found at the level of PDZ, SH3, and guanylate kinase 
domains (figure 20). This suggests a potential perturbation of TJP2’s function, i.e., 
organizing tight and adherent junctions by binding to the cytoplasmic C termini of 
junctional transmembrane proteins and linking them to the actin cytoskeleton. 
Indeed, one variant (p.R353W) is predicted to affect the homo- and hetero-dimerization 
interface with TJP1 (figure 21 page 77). 
 
Figure 20. TJP2 lollipops. Legend is the same of other lollipops figures. V15L, K16E and R24H are not present in figure. 
T93M in the text is at position 62 in the figure, Q159K is 128, A287V is 256, R353W is 322, M699I is 668 and I906T is 875. 
This is due to the following reason: our VCF were generated from ENST00000539225.1, NM_001170416 as reference 
transcript, but we were forced to use NM_004817.3 for annotation of variants on protein sequences through the lollipop 




Figure 21. PFIC protein structures. Non-synonymous mutation annotations on available 3D structures as assessed 
through Mechismo, are displayed following the same colouring scheme as in figures 20, 21, 22. Labels in parenthesis 
indicate mutations with no structural information. PDB numbers for crystalized protein structures as follow. ATP8B1: 
3TLM, Crystal Structure of Endoplasmic Reticulum Ca2+-ATPase (SERCA) from Bovine Muscle of Bos taurus. ABCB11 
and ABCB4: 4F4C, Crystal Structure of the Multi-Drug Transporter, from Caenorhabditis elegans. TJP2: 2OSG, PDZ and 
SH3 domains from Homo sapiens. 
 
 
3.2.5 FIC patients’ profile 
Excluding the common SNP p.V444A on ABCB11, (present in 83.3% of cases) and p.I237= 
on ABCB4 (33%), 26/48 patients (58.3%), have at least one mutation in one or more genes: 8 
patients had only one mutated allele while 18 patients had two or more mutated alleles. 
ABCB11 and TJP2 resulted the most affected genes and they are mutual exclusive.  
It is possible that patients with multiple alleles mutated have more severe phenotypes by a 
synergistic effect at different bile transporters’ sites as predicted by structural analysis. 
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However, patients having ≥ 2 non-synonymous mutations (with at least one predicted 
P/LP), tend to have higher liver stiffness comparing to patients with < 2 non-synonymous 
mutations (kPa at Fibroscan 7.9 vs. 4.9, p = 0.028), indicating a potential role of these variants 
as disease modifiers. 
Significant differences between subjects with and without P/LP mutations were not 
observed in sex, age at symptoms presentation, and the following risk factors for PFIC: DIC 
history, family or personal history of ICP, juvenile cholelithiasis and family history for 
cholestatic diseases (table 9). However, at least one of these risk factors was present in 9/11 
patients with P/LP mutations. Patients with P/LP mutations had more frequently neonatal 
jaundice (45.5 vs. 13.5%, p = 0.036) and itching (54.5 vs. 18.9%, p = 0.029). Regarding 
laboratory tests, significant differences were observed between the two subgroups only in 
terms of bile acids concentration (23.8 [4.4–403] vs. 8.8 [2.3–114], p = 0.003). 
Liver stiffness was greater in subjects with P/LP mutations in comparison with the others 
(8.1 [3.3–35.8] vs. 4.8 [3.1–29.9], p = 0.009). All subjects of the first group showed histological 
features of intrahepatic cholestasis while 72% of patients without P/LP mutations presented 
it (p = 0.018).  
 
Table 9. Main features of patients according to presence of P/LP mutations. N: number, Tot N: total number, 
DIC: drug-induced cholestasis, SD: standard deviation, P/LP: mutations pathogenic and likely mutations, ICP: 
intrahepatic cholestasis of pregnancy, AP: alkaline phosphatase, ALT: alanine transaminases, kPa: kilopascal 
(Vitale et al. J Gastroenterol. 2018). 
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3.3  Results from fifteen-gene panel analysis 
During the three-years PhD-project, 179 patients were enrolled at the S.Orsola-Malpighi 
Policlinic in Bologna. In about two years of the project we performed the four-gene analysis 
on 96 patients, while in about the last year of the project we used the new fifteen-gene panel 
for the molecular analysis of PFIC on 80 patients. In addition to the NGS variants validation, 
Sanger sequencing were executed on three patients to confirm the variant segregation of 
their relatives.  
A total of 184 different variations was identified in all patients in the two panels. To assess 
the variant’s category, we have adopted more stringent ACMG standards criteria than ones 
mentioned before. Other two tools helped us to understand the role of the variants. The first, 
ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) is a freely accessible, public archive of 
reports of the relationships among human variations and phenotypes, with supporting 
evidence, contributing to define the pathogenicity of a certain allele. The second, VarSome 
94, is a search engine for human genomic variation, which enables users to look up variants 
in their genomic context, collects data from multiple databases in a central location and most 
importantly, aims to enable the community to freely and easily share knowledge on human 
variation. In the next paragraphs variants certainly benign will not described.  
 
3.3.1 ATP8B1 variants 
More than 100 different mutations have been detected in ATP8B1 gene so far in patients 
with PFIC1 (HGMD®), but the number of identified variants with no clear definition of 
pathogenicity is still increasing.  
We identified 8 VUS, 1 likely benign and 2 benign. Among VUS, the third patient carrying 
the N45T in our cohort (¶ 3.2.1) is a 65-year-old male subjected to fifteen-gene panel analysis 
who has also LB variants in ABCB11, ABCB4, MYO5B, SLCO1B1 and SLCO1B3.  
An 18-year-old man, who presented histological signs of biliary ductopathy, increased 
levels of bile acids and an history of metabolic liver disease in the father, carries two VUS. 
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The c.208G>A (p.D70N) in exon 3 is a rare variant (MAF: 0.004) associated to BRIC 
(CM043812, Klomp et al. 2004) and the c.1288A>G (p.K430E) in exon 13 is a novel variant 
predicted to be pathogenic by in-silico predictions. The patient had also LB variants in 
ABCB11, ABCC2, SLCO1B1 and SLCO1B3.  
The c.913T>A (p.F305I) in exon 10 was previously associated to PFIC 56 and present in a 58-
year-old woman who had also LB variants in ABCB11 gene.  
The c.1177A>G (p.I393V) in exon 12 is present in HGMD (CM1716476, Meng et al. 2017), it 
is a rare variant (MAF: 0.006) and was identified in 2 patients. 
The c.1498T>C (p.Y500H) in exon 15 was previously associated to PFIC (CM043818, Klomp 
et al. 2004), but all the other tools referred to it as VUS. 
The c.2771A>G (p.Y924C) in exon 23 is a rare VUS (MAF: 0.00004) with discordant 
predictions of pathogenicity. It was found in a 68-year-old man with other two VUS in 
MYO5B and NOTCH2. Other LB variants were found in ABCB11, ABCB4, ABCC2, JAG1, 
SLCO1B1 and TJP2.  
The c.3589G>T (p.V1197L) in exon 28 is a rare VUS ever described before, but all 
bioinformatic tools agree for no functional impact for it. This variant was found in a patient 
with a frameshift in JAG1 (¶ 3.3.7). 
The c.3707C>G (p.A1236G) in exon 28, is a novel variant predicted not to affect the protein 
and, even for the poor knowledge about it, it is classified as VUS. 
The only LB variant found in ATP8B1 is once again the c.2855G>A (p.R952Q) in exon 23. 
This variant is a polymorphism because of the MAF (0.12). It has also the same frequency 
between the two major population databases and our patients’ cohort: 0.12 for European 
population by gnomAD (genome aggregation database, 
https://gnomad.broadinstitute.org/), 0.11 for TSI (Tuscan from Italy) in 1000Genome and 





ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
2 68C>T P23L rs1345769999 - VUS - LP 1 
2 134A>C N45T CM0510091/rs146599962 0.007 VUS - VUS 3 
3 208G>A D70N CM0438122/rs34719006 0.00449 VUS VUS VUS 1 
7 607A>G K203E CM0510101 DM?/rs56355310 0.001 VUS VUS VUS 2 
10 913T>A F305I CM17222763 DM?/rs150860808 0.001 LB LB/VUS VUS 1 
12 1177A>G I393V CM17164764/rs34315917 0.00615 LB B/LB/VUS VUS 2 
13 1288A>G K430E novel - VUS - VUS 1 
15 1498T>C Y500H CM0438182/rs147642236 0.000589 LB VUS VUS 1 
23 2771A>G Y924C rs145287364 0.0000439 VUS VUS VUS 1 
23 2855G>A R952Q rs12968116 0.121 B B/LB LB 27 
28 3589G>T V1197L rs1376578283 0.0000122 LB VUS VUS 1 
28 3655C>G D1219H rs753339861 0.0000183 VUS VUS LP 1 
28 3707C>G A1236G novel - VUS - VUS 1 
Table 10. All identified ATP8B1 variants in all patients during the project. 1. Painter (2005) Eur J Hum 
Genet; 2. Klomp (2004) Hepatology; 3. Dröge (2017) J Hepatol; 4. Meng (2017) JAMA; DM?: likely disease-
causing mutation; N: number of cases. benign variants are not shown. 
 
3.3.2 ABCB11 variants 
So far, more than 400 missense variants have been reported in ABCB11 gene on HGMD. 
We identified 11 variants: 3 VUS, 4 LB variants and 4 benign variants (not reported here). 
Among VUS, we identified the novel variant c.209T>C (p.F70S) in exon 5 combined to a 
frameshift in ABCB4 (§ 3.3.3). 
Always in the exon five, the c.383G>A (p.R128H) is a rare variant (MAF: 0.00003) never 
associated to the disease and with discordant bioinformatic predictions. It was found in a 
50-years-old man carrying another VUS in NOTCH2 (F1209V) and LB variants in MYO5B, 
SLCO1B1 and SLCO1B3. 
The synonymous variant c.2739A>G (p.L913=) was classified as VUS by Varsome because is 
absent from controls in Exome Sequencing Project, 1000 Genomes Project, or Exome 
Aggregation Consortium (MAF: 9*10-6) and it is located in a mutational hot spot and/or 
critical and well-established functional domain (e.g., active site of an enzyme). HSF (Human 
Splicing Finder) analysis revealed a potential alteration of splicing by activation of an exonic 
cryptic donor site (algorithm: HSF Matrices) or by creation of an exonic ESS site. ESSs inhibit 
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or silence splicing of the pre-mRNA and contribute to constitutive and alternate splicing. 
However, this in-silico analysis should be confirmed with other in-vitro studies. 
Among LB variants, we identified the c.957A>G (p.G319=) in exon 10. This variant was 
previously described by Byrne et al. 2009 as splicing modificatory by in vitro functional 
studies (CM092797). Nevertheless, due to the high and different frequencies in worldwide 
population (spanning from 0.327 in African to 0.000613 in Est Asian) it is considered LB in 
our cohort, formed mainly by European population. 
The following two LB variants are described in the previous section (¶ 3.2.2): the c.1331T>C 
(p.V444A) in exon 13 and c.2029A>G (p.M677V) in exon 17. At the end of the project the 
polymorphism c.1331T>C was present in 153/176 patients (86%), while population data from 
1000 Genome in TSI is 63% and allele frequency from gnomAD is 59%. 
The polymorphism c.2029A>G (p.M677V) was present in 20/176 (11%), 0.017 gnomAD 
0.0327 1000 Genome. 
The c.3084A>G (p.A1028=) in exon 24 is a polymorphism present in HGMD (CM092757, 
Byrne et al. 2009) with additional functional evidence and associated with primary biliary 
cirrhosis. It is also present in dbSNP (rs497692) and gnomAD with a G allele frequency of 
55%. In our cohort, instead, frequency of G allele is 148/176 (84%). 





ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
5 209T>C F70S novel - VUS - VUS 1 
5 278A>C Y93S rs1185733805 0 VUS - VUS 1 
5 383G>A R128H rs181533618 0.0000268 LB VUS VUS 1 
6 403G>A E135K CM0927371/rs752992432 0.0000579 VUS LP LP 1 
9 833G>A G278E novel - VUS - VUS 1 
10 957A>G G319= CM0927971 FP/rs7563233 0.02 LB LB LB 20 
12 1268A>G H423R rs147522210 0.000231 VUS - VUS 1 
13 1331T>C V444A CM0715252 DFP/rs2287622 0.5972 B LB LB 153 
14 1568C>G A523G CM16111663/rs769652427 0.0000267 VUS - LP 2 
15 1789G>C V597L novel - VUS - VUS 1 
17 2029A>G M677V CM17237874 DM?/rs11568364 0.0178 B LB LB 20 
21 2494C>T R832C CM0676175/rs772294884 0.00000888 LP LP LP 1 
22 2739A>G L913= rs775098358 0.000008 VUS - VUS 1 
24 3084A>G A1028= CM0927571 DFP/rs497692 0.5 B B LB 148 
25 3297delC S1100QfsX38 CD15138056 0 P - P 1 
25 3382C>T R1128C CM0814827 0 LP - LP 1 
Table 11. All identified ABCB11 variants in all patients during the project. 1. Byrne (2009) Hepatology; 2. 
Lang (2007) Pharmacogenet Genomics; 3. Vitale (2016) Ann Hepatol; 4. Dröge (2017) J Hepatol; 5. Walkowiak 
(2006) J Pediatr Gastroenterol Nutr; 6. Giovannoni (2015) PLoS One; 7. Strautnieks (2008) Gastroenterology; FP: 
in vitro or in vivo functional polymorphism; DFP: disease-associated polymorphism with additional 
functional evidence; DM?: likely disease-causing mutation; N: number of cases; benign variants are not 
shown. 
 
3.3.3 ABCB4 variants 
More than 300 missense/non sense variants have been reported in ABCB4 gene on HGMD. 
We identified 15 variants divided as follows: 3 P/LP mutations, 2 VUS, 3 LB variants and 7 
benign (not reported here). 
As regard P/LP mutations, the c.959C>T (p.S320F) in exon 9 was previously associated to 
PFIC (CM013506) 75 as disease-causing mutation. This mutation was found in a 37-year-old 
female with a familial history of biliary lithiasis. The patient had also LB variants in ABCB11 
(V444A), SLCO1B1, SLCO1B3 and VPS33B (case 1 in table 17). 
Among disease-causing variants, the small insertion c.1135_1136insAA (exon 11) causes an 
aminoacid change (Lysine) and a translation’s shift (p.S379Kfs*35) that induce a premature 
stop codon after 35 aminoacids. The novel mutation produces a 416 aminoacids long 
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protein, 1/3 of the wild-type protein (1286aa). This variant was found in a 58-year-old female 
with familial history of ICP and cholelithiasis and a F1/F2 Fibroscan score of 7 kPa (case 2 
in table 17). 
The c.1442T>G (p.L481R) in exon 13 was previously described by Degiorgio et al. 2014 and 
it is present in HGMD (CM144425). We found this mutation in a 33-year-old female with 
high GGT and alkaline phosphatase with a familial history of hepatic disease with high GGT 
(case 3 in table 17). 
Two VUS were identified: c.523A>G (p.T175A) in exon 6 and c.1769G>A (p.R590Q) in exon 
15. The latter was seen three times in our cohort, and both were previously described in 
HGMD (CM013505 and CM075942). They were reclassified by ClinVar and Varsome as 
VUS. 
LB variants were three: c.579A>G (p.G193=) in exon 7, c.711A>T (p.I237=) in exon 8 and 
c.1954A>G (p.R652G) in exon 16. 
The G193= is a novel variant found in heterozygous in a 74-year-old male without LP 
mutations. Varsome classifies this variant as VUS, because it is located in a mutational hot-
spot without benign variations and it is absent from controls in the main population 
databases, like Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation 
Consortium. The variant is also a synonymous for which splicing prediction algorithms 
predict no impact to the splice consensus sequence nor the creation of a new splice site. The 
patient had also heterozygosity for I237=. This variant is present on HGMD as previously 
associated polymorphism to ICP (CM031116). We found it in 54/179 patients (30%), while 
in gnomAD MAF is 0.177 and 0.20 in 1000 Genomes. 
The c.1954A>G (p.R652G) in exon 16 was previously associated to PFIC in HGMD. After 
revision by some authors, now it is considered a disease-associated polymorphism. We 
found it in 33/179 patients (18%), while in gnomAD MAF is 0.07 in European population 
and in 1000 Genomes is 0.10 in TSI population. 





ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
4 217C>G L73V CM1103121 DM?/rs8187788 0.0013 VUS VUS VUS 1 
6 523A>G T175A CM0135052 DM?/rs58238559 0.01 VUS B/LB/P VUS 2 
7 579A>G G193= novel - VUS - LB 1 
8 711A>T I237= CM0311163/rs2109505 0.17 B LB LB 54 
9 959C>T S320F CM0135063/rs72552778 0.000291 LP VUS/LP LP 1 
10 1091C>T A364V CM0759464 - VUS - LP 1 
11 c.1135_1136insAA S379KfsX35 novel - P - P 1 
11 1028A>G Y403C novel - LP - LP 1 
13 1442T>G L481R CM1444255 - LP - LP 1 
15 1769G>A R590Q CM0759424 DM?/rs45575636 0.007 VUS VUS VUS 3 
16 1954A>G R652G CM0728146 DP/rs2230028 0.0737 B B LB 33 
16 2014A>T K672* novel - P - P 1 
19 2324C>T T775M CM0759384/rs148052192 0.001 VUS - LP 1 
Table 12. All identified ABCB4 variants in all patients during the project. 1. Colombo (2011) J Pediatr 
Gastroenterol Nutr; 2. Rosmorduc (2001) Gastroenterology; 3. Mullenbach (2003) J Med Genet; 4. Degiorgio (2007) 
Eur J Hum Genet; 5. Degiorgio (2014) Eur J Hum Genet; 6. Liu (2007) Gastroenterology; DM?: likely disease-
causing mutation; DP: disease-associated polymorphism; N: number of cases; benign variants are not shown. 
 
 
3.3.4 TJP2 variants 
Besides many variants identified with the four-gene panel in TJP2, we identified also several 
variants in the new genetic panel, confirming the high variability of this gene. It is also true 
that this is a relatively new gene involved in the disease and we are finding always missense 
variants in a gene for which primarily truncating variants are known to cause the disease.  
We identified the VUS c.1411A>G (p.S471G) in exon 8, c.1669G>T (p.A557S) exon 11 and 
c.2530T>G (p.F844V) in exon 17. 
We found the S471G in a 48-year-old male born with Tetralogy of Fallot and with a familial 
history of hepatic cirrhosis. The patient had also variants in ABCC2, JAG1 and SLCO1B1. 
The A557S is a very rare variant (MAF: 0.0000791) found in a 44-year-old female with no 
clinical information. 
The F844V is a novel variant and was found in a 31-year-old female with no clinical 
information, who carries one VUS in MYO5B. 
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LB variants identified were V15L in two unrelated patients and the c.1571G>A p.R524K. All 
identified TJP2 variants during the project are in table 13. Eleven benign variants were also 
found more times in several patients. 
 
TJP2 
ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
1 43G>C     V15L rs73450853 0.0000715 LB B LB 2 
1 46A>G K16E rs151117327 0.0006 VUS VUS VUS 1 
3 278C>T          T93M CM17141901 DM?/rs138241615 0.00239 VUS LB/VUS LP 3 
5 860C>T A287V rs1266640794 - LB - LB 2 
6 1057C>T R353W rs759484247 0.00004         VUS - LP 2 
8 1411A>G S471G rs762001932 0.0000352 VUS - VUS 1 
10 1571G>A R524K rs41277901 0.00179 LB B/LB LB 3 
11 1669G>T A557S rs746223152 0.0000791 VUS VUS VUS 1 
11 1686C>T     V562=            rs781308072 0.00000879  VUS VUS LB 1 
14 2097G>A M699I rs34774441 0.0629 B B/LB LB 28 
14 2224T>C S742P rs35797487 0.000387 B B/LB LB 1 
17 2530T>G F844V novel - VUS - VUS 1 
18 2717T>C I906T rs756322608 0.0000176 VUS - LP 1 
21 3122C>T S1041F rs41277907 0.08 B B/LB LB 31 
22 3465G>A       T1155= rs745427593   0.0000439  VUS LB/VUS LB 2 
Table 13. All identified TJP2 variants in all patients during the project. 1. Dixon (2017) Sci Rep; DM?: likely 
disease-causing mutation; N: number of cases; benign variants are not shown. 
 
3.3.5 ABCC2 variants 
Just forty ABCC2 mutations (missense and nonsense) have been described in HGMD so far. 
We found 17 variants in ABCC2 gene. One is LP mutation, five are VUS, five are LB variants 
and six are benign variants. 
The only LP mutation identified is the c.2303G>A (p.R768Q) in exon 18. This variant is 
present in dbSNP (rs536840524), it is very rare (MAF: 0.0000352) and it is found at an amino 
acid residue where a different missense change determined to be pathogenic and is 
described in HGMD (R768W). We found this mutation in a 48-year-old male with high GGT 
and alkaline phosphatase and having also tree LB variants in ABCB11, TJP2 and MYO5B 
(case 4 in table 17). 
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Among VUS, the c.1109C>T (p.A370V) in exon 9 is also rare (MAF: 0.0000264) and was 
considered LB/VUS respectively by Varsome and ClinVar. We found it in a 55-year-old male 
having LB variants in ABCB4, SLCO1B1, SLCO1B3 and TJP2. No clinical and familial 
information were provided. 
The c.1249_1250inv (p.V417T) in exon 10 is a private variant does not present in population 
databases. In-silico predictions are discordant, and we found it in a 35-year-old female with 
history of itching and cholestatic disease. The brother of the proband, sequenced in Sanger, 
has the same variant of the sister. They have also LB variants in ABCC2 (P871R) and MYO5B. 
The c.3236G>A (p.R1079Q) in exon 23 was present in a 50-year-old female with other LB 
variants in ATP8B1, ABCB11, ABCB4 and MYO5B. 
The c.3500T>C (p.V1167A) in exon 25 is a rare variant (MAF: 0.000466) with poor 
information and predicted to be deleterious/probably damaging by SIFT and PolyPhen. We 
found it in a 21-year-old female with juvenile lithiasis and cholestatic disease. The patient 
carried also LB variants in ABCB11, ABCB4, SLCO1B1 and SLCO1B3. 
The c.4430C>T (p.T1477M) in exon 31 is a VUS with discordant predictions of pathogenicity. 
We found it in a 56-year-old male with another VUS in GPBAR1 and many LB variants in 
ATP8B1, ABCB11, ABCB4, SLCO1B1, SLCO1B3 and TJP2.  
Among LB variants, the c.842G>A (p.S281N) in exon 7, the c.2546T>G (p.L849R) in exon 19, 
the c.3107T>C (p.I1036T) in exon 23, the c.3563T>A (p.V1188E) in exon 25 and the c.4544G>A 
(p.C1515Y) in exon 32. Only the last one seems to be involved in the disease because it is 
reported in HGMD as reducing the pump efflux activity (CM119536).  





ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
7 842G>A S281N rs56131651 0.00794 LB VUS/LB LB 2 
9 1109C>T A370V rs144390464 0.0000264 LB VUS/LB VUS 1 
10 1249_1250inv V417T novel - LB VUS VUS 1 
18 2303G>A R768Q rs536840524 0.0000352 LP VUS LP 1 
19 2546T>G L849R rs17222617 0.0179 LB LB LB 3 
23 3107T>C I1036T rs45441199 0.00821 LB B LB 1 
23 3236G>A R1079Q rs145672804 0.00821 LB VUS VUS 1 
25 3500T>C V1167A rs140680467 0.000466 VUS VUS VUS 2 
25 3563T>A V1188E rs17222723 0.056 B LB LB 16 
31 4430C>T T1477M rs142573385 0.00173 LB VUS VUS 1 
32 4544G>A C1515Y CM1195361 FP/rs8187710 0.057 B LB LB 17 
Table 14. All identified ABCC2 variants. 1. Elens (2011) Pharmacogenet Genomics; FP: in vitro or in vivo 




Figure 22. ABCC2 lollipops. Protein sequence annotations of ABCC2 variants displayed as red lollipops. Diameters are 
proportional to the number of patients affected. Blue, green and khaki lollipops indicate respectively phosphorylation, 
acetylation and ubiquitylation sites. The Y93F is a false positive. 
 
3.3.6 GPBAR1 variants 
GPBAR1 gene encodes for the G Protein-Coupled Bile Acid Receptor 1. This enzyme 
functions as a cell surface receptor for bile acids. Treatment of cells expressing this GPCR 
with bile acids induces the production of intracellular cAMP, activation of a MAP kinase 
signalling pathway, and internalization of the receptor. The receptor is implicated in the 
suppression of macrophage functions and regulation of energy homeostasis by bile acids. 
Eight mutations have been described in HGMD so far. Associated phenotypes are primary 
sclerosing cholangitis, heterotaxy and severe obesity with an early onset. 
89 
 
The gene has only two exons and the coding region starts in exon 2. We found three VUS 
and one benign variant. 
The c.648_649inv (p.A217P) is a VUS for VarSome and does not have any information about 
frequency in the population. It has the same aminoacid change of one of the eight variants 
reported in HGMD (CM105602, Hov et al. 2010) as a functional polymorphism with in vitro 
or in vivo evidences. However, we found a different nucleotide change, the c.648_649inv that 
is a deletion/insertion: GG are substituted by CC (delGGinsCC) and this is called 
“inversion” and our variant is a novel. 
We found this variant in a 56-year-old male with no clinical information and who carries 
also another VUS in ABCC2 and many LB variants in ATP8B1, ABCB11, ABCB4, SLCO1B1, 
SLCO1B3 and TJP2. 
The c.856C>G (p.R286G) is another novel VUS predicted tolerated and possibly damaging 
respectively by SIFT and PolyPhen. We found it in a 53-year-old female carries also LB 
variants in ABCB11, ABCB4, JAG1, MYO5B and SLCO1B1. The patient has a familial history 
for biliary calculi and breast cancer and has low GGT but high AP and transaminases and a 
8.7 kPa (F2) at Fibroscan (score from F0 to F4, F>2 significant fibrosis). 
The c.923G>C (p.R308P) is present in dbSNP (rs200024655) with no frequency information 
and it has discordant bioinformatics predictions of pathogenicity (SIFT: not tolerated, 
PolyPhen: benign). We found it in a 36-year-old female with no clinical information. The 
patient has also LB variants in ABCB11, ABCB4, ABCC2 and a VUS in MYO5B. 
All identified GPBAR1 variants during the project are in table 15. 
 
GPBAR1 
ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
2 648_649inv A217P novel - VUS - VUS 1 
2 856C>G R286G novel - VUS - VUS 1 
2 923G>C R308P rs200024655 - VUS - VUS 1 
Table 15. All identified GPBAR1 variants. N: number of cases; benign variants are not shown.  
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3.3.7 JAG1 variants 
JAG1 gene has 26 exons and produces a protein of 1218 aminoacids. It is associated with 
Alagille syndrome 1 and Tetralogy of Fallot.  
We identified 13 variants: one was pathogenic, one was VUS, two LB and nine benign 
variants. 
The causative mutation c.2029dup (p.H677Pfs*12) in exon 16 is an insertion of one C 
nucleotide that cause the frameshift mutation H677Pfs*12 with a premature truncated 
protein. We found it in a 47-year-old male presenting biliary calculi in adolescence with 
subsequent cholecystectomy and developing a chronic renal failure and HCC (case 5 in 
table 17). No information about his family were provided. 
The VUS c.3638G>A p.R1213Q in exon 26 is present in HGMD (CM023743, Kohsaka et al. 
2002). It is a rare variant (MAF: 0.0000527) and it is considered VUS by VarSome and 
ClinVar. It was found in a 54-year-old woman with no clinical information. 
The two LB variants were the c.436G>A (p.V146I) in exon 3 and the c.2612C>G (p.P871R) in 




ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
3 436G>A V146I rs6040067 0.000193 B B/LB LB 1 
16 c.2029dup H677Pfs*12 novel - P - P 1 
22 2612C>G P871R rs35761929 0.0669 B B/LB LB 13 
26 3638G>A R1213Q CM0237431/rs138007561 0.0000527 VUS VUS VUS 1 
Table 16. All identified JAG1 variants. 1. Kohsaka (2002) Hepatology; N: number of cases; Benign variants 
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3.3.8 MYO5B variants 
We identified 22 variants: 6 VUS, 7 likely benign and 9 benign variants.  
Among VUS, the c.1069T>C (p.Y357H) in exon 10 is a very rare because it was seen just in 
one European female (MAF: 9*10-6) before us. It is located in a mutational hot spot in Myosin 
head functional domain without benign variation. We found it in a 36-year-old female with 
no clinical information. LB variants were found in ABCB11, ABCB4, ABCC2 and MYO5B. 
The c.1834A>G (p.I612V) in exon 15 is also a rare variant and located in the functional 
domain of the Myosin head and we found it in a 67-year-old female with low GGT, a familial 
history of hepatic disease, ICP and juvenile cholelithiasis. The patient had also LB variants 
in ABCB11, ABCB4, ABCC2, one LB and the following VUS in MYO5B. 
The c.2123G>A (p.R708Q) in exon 18 has an allele frequency of 0.0009, bioinformatic 
predictions are deleterious but still poor information are available to assess the role of this 
variant. We found this variant in two unrelated patients. The second is a 21-year-old male 
with high GGT and AP with a Fibroscan score of 10.7 kPa (F3) and neonatal jaundice. 
Multiple LB variants were found: ABCB11, ABCB4, ABCC2, MYO5B, SLCO1B1 and 
SLCO1B3. 
The c.2343G>C (p.K781N) in exon 19 was found in a 71-year-old female with high ALT, GGT 
and AP and a Fibroscan score of 6 kPa (F1) and no familiarity. The patient had also LB 
variants in ABCB11 and ABCB4. 
The c.5144A>G (p.N1715S) in exon 38 is a novel variant predicted to be pathogenic by the 
main bioinformatic tools. We found it in a 68-year-old male (BMI = 29) with high bilirubin, 
AP and slightly GGT. The patient had also the higher Fibroscan score in the cohort: 75 kPa 
(F4 starts from 13 kPa). The patient’s haplotype is very interesting, with another VUS in 
ATP8B1 and different LB variants in ABCB11, ABCB4, ABCC2, JAG1, NOTCH2, SLCO1B1 
and TJP2. 
The last VUS, c.5411G>C (p.R1804P) in exon 40 is also rare (MAF: 0.0000443) and we found 
it in a 31-year-old female with no clinical information, but carrying also LB variants in 
ABCB11, ABCB4, ABCC2 and the novel VUS in TJP2 (¶ 3.3.4). 
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Likely benign variants identified were: the c.145G>C (p.E49Q) and c.176T>C (p.L59P) in 
exon 3, the c.921G>T (p.K307N) in exon 8, the c.2753G>A (p.R918H) in exon 21, the 
c.3645C>T (p.D1215=) in exon 28, the c.4145C>T (p.T1382M) in exon 31 and c.5395-6C>T in 
IVS39. All identified MYO5B variants during the project are in table 18. 
 
MYO5B 
ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
3 145G>C E49Q rs141998504 0.0137 LB LB LB 1 
3 176T>C L59P rs78626055 0.0258 B B/LB LB 4 
8 921G>T K307N rs17659179 0.0633 B B/LB LB 4 
10 1069T>C Y357H rs772554828 0.000008932 VUS - VUS 1 
15 1834A>G I612V rs1267348047 0.00000883 VUS - VUS 1 
18 2123G>A R708Q rs201670299 0.0009 VUS - VUS 2 
19 2343G>C K781N rs61737448 0.00204 LB - VUS 1 
21 2753G>A R918H rs2298624 0.139 B LB LB 12 
28 3645C>T D1215= rs200991250  0.000339 VUS - LB 1 
31 4145C>T T1382M rs145598498 0.00365 B LB LB 1 
38 5144A>G N1715S novel - VUS - VUS 1 
IVS39 5395-6C>T - rs140275825 0.00459 LB VUS LB 1 
40 5411G>C R1804P rs201080553 0.0000443 VUS VUS VUS 1 
Table 18. All identified JAG1 variants in all patients during the project. N: number of cases; benign 
variants are not shown. 
 
3.3.9 NOTCH2 variants 
NOTCH2 gene has been associated to Alagille syndrome 2 and Hajdu-Cheney syndrome so 
far. We identified 11 variants: 1 P/LP mutation, 1 VUS, 4 LB and 5 benign variants. 
The c.6007C>T (p.R2003*) in exon 33 is a nonsense mutation described in HGMD 
(CM1110718, Kamath et al. 2012) as a disease-causing mutation associated to Alagille 
syndrome. We identified this mutation in a 26-year-old male born with ileal volvulus 
syndrome and now having high GPT and AP, low GTT F1 at Fibroscan and carrying other 
LB variants in ABCB11, ABCC2, SLCO1B1 and SLCO1B3 (case 6 in table 17). 
The c.2765A>G (p.N922S) in exon 18 is a VUS not found in dbSNP. This missense variant 
was seen in two European individuals (as reported by gnomAD), so the MAF is very low 
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(0.00001553). The variant is classified as VUS because it is in a gene for which primarily 
truncating variants are known to cause disease and multiple lines of computational 
evidence support a deleterious effect on the gene or gene product. We found it in a patient 
with high GTP, AP, low GGT and 6.7 kPa at Fibroscan (F1). The grandmother of the proband 
had NAFLD. The patient had also LB variants in ATP8B1, ABCB11, JAG1, SLCO1B1 and 
TJP2. 
The LB variants were c.1918G>T (p.V640F) in exon 12, c.3625T>G (p.F1209V) in exon 22, 
c.3980A>G p.D1327G in exon 24 and c.6223G>A p.V2075M in exon 34. They are all rare 
variants. All identified NOTCH2 variants during the project are in table 19. 
 
NOTCH2 
ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
12 1918G>T V640F rs782463006 0.0000353 LB - LB 1 
18 2765A>G N922S novel 0.00000882 VUS - VUS 1 
22 3625T>G F1209V CM1569981 DM?/rs147223770 0.00382 B LB LB 3 
24 3980A>G D1327G CM1650622 DM?/rs61752484 0.00763 B B LB 3 
33 6007C>T R2003* CM11107183/rs312262801 - P P P 1 
34 6223G>A V2075M rs150516342 0.00198 B LB LB 1 
Table 19. All identified NOTCH2 variants in all patients. 1. Aloraifi (2015) FEBS J; 2. Priest (2016) PLoS 
Genet 3. Kamath (2012) J Med Genet; DM?: likely disease-causing mutation; N: number of cases; benign 
variants are not shown. 
 
3.3.10 Other genes 
The NR1H4 gene has 3 mutation recorded in HGMD, it is a recently PFIC-associated gene 
and for this reason its knowledge is still poor. Our results are in accordance with literature. 
We found just one variant: the c.548T>C (p.M183T) in exon 3. It is a rare variant (MAF: 
0.00282), computational analysis supports a deleterious effect on the gene but ClinVar refers 
to it as likely benign variant. For this reason, it is very difficult to assess the role of this 
variant. We found it in a 67-year-old male with PFIC and a score of 28 kPa at Fibroscan (F4). 
The patient had also LB variants in ABCB11, ABCB4, SLCO1B1 and TJP2. 
CLDN1 is a little gene with a transcript length of 3481 bp divided into 4 exons. Its translation 
produces a 211 aminoacid long protein. The knowledge about this gene is still poor, in fact, 
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there are only two nonsense mutations described in HGMD so far. The phenotypes 
associated with these two mutations are ichthyosis, alopecia and sclerosing cholangitis. 
We identified just one VUS and three benign variants. 
The only variant identified in CLDN1 gene is the c.565A>G p.K189E in exon 4. The K189E is 
very rare, with a MAF in European population of 0.000149 and it is predicted to be 
deleterious and possibly damaging by SIFT and PolyPhen. We found it in a 47-year-old male 
having a severe mutation in JAG1 (§ 3.3.7) and other variants. 
The SLC25A13 gene causes intrahepatic cholestasis by citrin deficiency (NICCD). In this 
gene we found just 4 variants: 1 VUS, 1 LB and 2 benign variants. 
The c.190G>A (p.V64M) in exon 3 is a novel variant does not present in HGMD. The 
aminoacid change from Valine to Methionine is predicted to affect the protein by SIFT and 
PolyPhen, however in this gene primarily truncating variants are known to cause disease. 
We found it in a 47-year-old female with ICP and normal GGT. Fibroscan analysis revealed 
a score of 7.9 kPa (F2).  
The synonymous c.609A>G (p.L203=) is defined VUS by VarSome. Because it is a 
synonymous (silent) variant for which splicing prediction algorithms predict no impact to 
the splice consensus sequence nor the creation of a new splice site, we refer to it as LB 
variant. 
In the SLCO1B1 gene we found 4 LB variants and 4 benign variants. 
The c.317T>C (p.I106T) in exon 4, the c.388A>G (p.N130D) in exon 5, c.521T>C (p.V174A) in 
exon 6 and c.1929A>C (p.L643F) in exon 15.  
The frequency of the SNP c.388A>G (p.N130D) in our cohort is higher than the population 
one (MAF: 0.612 vs 0.404). This variant is described in HGMD as disease-associated 
polymorphism with additional functional evidence and an altered transport activity 
(CM043776). In the present study we demonstrated that this SNP is significantly associated 
to normal AST levels (p = 0.047) and low Fibroscan scores (p = 0.044) by contingency tables 
(¶ 3.4). 
In the SLCO1B3 gene we found 4 LB and 6 benign variants. SNPs were c.767G>C (p.G256A) 
in exon 9, c.1074C>T (p.Y358=) in exon 10, c.1347A>G (p.A449=) in exon 12 and c.1857A>T 
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(p.V619=) in exon 15. For SNP c.767G>C, p.G256A (rs60140950), the frequency in our cohort 
is higher than the population one (MAF: 0.275 vs 0.159). By the de Finetti association 
analysis, we shown that homozygous patients carrying Alanine in both allele have an 
increased risk for the disease: OR = 5.053 (p = 0.02877) for CC genotype (¶ 3.4). 
Gissen et al. (2004) identified mutations in the VPS33B gene as the cause of the 
arthrogryposis-renal dysfunction-cholestasis syndrome. We found nine variants in this 
gene: three VUS, two LB and four benign variants. Among VUS, the c.163G>A (p.V55I) in 
exon 2, c.944G>A (p.R315Q) in exon 13 and the c.1170+5G>A in IVS15. 
The V55I is very rare (MAF: 0.0000176) and present in dbSNP. It was found in a 54-year-old 
woman with no clinical information. The patient had also a VUS in JAG1 and LB variants in 
ABCB11, ABCC2, SLCO1B1 and SLCO1B3. 
The R315Q was found in a 56-year-old male with low GGT, HCC and a score of 12.8 kPa at 
Fibroscan (F3). The patient had also SNPs in seven genes: four LB variants in ABCB11, 
variants in ABCC2, MYO5B, NOTCH2, SLCO1B1, SLCO1B3 and TJP2. 
The c.1170+5G>A is predicted to alter the WT splicing donor site by HSF. We found this 
variant in a 44-year-old male with cryptogenetic cholestasis, high GGT and AP and a score 
of 4.9 kPa at Fibroscan (F0/F1). He showed a reduced expression of MDR3 protein at 
immunohistochemistry. ABCB11, ABCB4, and NOTCH2 LB variants were also identified in 





ex DNA (c.) Protein (p.) HGMD/dbSNP/novel MAF VarSome ClinVar our N 
NR1H4 
3 548T>C M183T rs61755050 0.00629 VUS LB VUS 1 
CLDN1 
4 565A>G K189E rs199998460 0.000149 VUS - VUS 1 
SLC25A13 
3 190G>A V64M novel - VUS - VUS 1 
6 609A>G L203= rs751566503 0.0000176 VUS - LB 1 
SLCO1B1 
4 317T>C I106T rs200227560 0.00074 LB - LB 1 
5 388A>G N130D CM0437761 DFP/rs2306283 0.404 B B/VUS LB 51 
6 521T>C V174A CM0437772 DFP/rs4149056 0.157 B B/drug response LB 30 
15 1929A>C L643F CM1201903 FP/rs34671512 0.05 B LB LB 8 
SLCO1B3 
9 767G>C G256A rs60140950 0.159 B B/LB LB 23 
10 1074C>T Y358= rs145036538 0.000159 VUS - LB 1 
12 1347A>G A449= rs79382866 0.00659 VUS VUS LB 1 
15 1857A>T V619= rs143827641 0.000961 VUS VUS LB 2 
VPS33B 
2 162T>C N54= rs769227036 0.0000439 VUS - LB 1 
2 163G>A V55I rs763310786 0.0000176 VUS - VUS 1 
13 944G>A R315Q rs145303578 0.00135 VUS VUS VUS 1 
15 1166G>A R389Q rs145070485 0.00238 LB - LB 1 
15 1170+5G>A IVS15 rs201431055 0.000114 VUS VUS VUS 1 
Table 20. All identified variants in NR1H4, CLDN1, SLC25A13, SLCO1B1, SLCO1B3 and VPS33B in all 
patients during the project. 1. Iwai (2004) Pharmacogenetics; 2. Pasanen (2008) Pharmacogenet Genomics; 3. Ramsey 
(2012) Genome Res; DFP: disease-associated polymorphism with additional functional evidence; FP: in vitro or 
in vivo functional polymorphism; N: number of cases; Benign variants are not shown. 
 
3.4  Statistical analysis 
Baseline features of the population analysed are shown in table 21. Laboratory findings 
were available for 56/80 patients, Fibroscan for 43 patients and BMI for 55. Familiarity for 
the disease, DIC and itching history, ICP history, neonatal jaundice and juvenile 
cholelithiasis episodes were not fully available for all patients and were not used for 





Table 21. Baseline features of the 80 patients in 
fifteen-gene analysis  
Sex 
41 male (51,3%) 
39 female (48,8%) 
Age 47.7 ± 15 (2-78) 
Laboratory  
AST (U/l) 39.0 (14-141) 
ALT (U/l) 63.2 (11-378) 
GGT (U/l) 146.2 (10-687) 
AP (U/l) 251.2 (56-719) 
Tot. Bilirubin (mg/dl) 1.1 (0.30-6.86) 
Dir. Bilirubin (mg/dl) 0.24 (0.08-0.65) 
Albumin (g/dl) 4.3 ± 0.5 (3.1-5.2) 
Fibroscan (kPa) 10.2 (2.7-75) 
BMI 25.3 (19-38) 
AST: aspartate transaminase; ALT: alanine transaminases; GGT: gamma-
glutamyl transferase; AP: alkaline phosphatase; kPa: kilopascal; BMI: body 




For laboratory data disease markers cut-offs were used to test the association between SNPs 
and biochemical parameters as follows: AST over 35 U/l, ALT over 45 U/l, GGT over 50 U/l 
and AP over 220 U/l. A BMI over the normal (> 25) was used as cut-off for this variable. 
Fibroscan scores were divided into two classes: F3 and F4 fibrosis (high fibrosis) against F1 
and F2 fibrosis (low scores). These two classes were used to test if SNPs were associated 
with high rates of hepatic fibrosis. With these analyses, some SNPs resulted as a protective 
or risk factors against the disease. Only statistically significant Pearson’s Chi squares are 
reported in tables 22 and 23. Table 22 shows protective SNPs.  
Patients carrying one allele of the ABCB11 variant c.270T>C (rs4148777) or the NOTCH2 
variant c.7341T>A (rs6685892) (there were not homozygous patients for these variants) seem 
to have a normal BMI. The ABCB11 variant c.957A>G (rs7563233) is significantly associated 
to normal GGT levels. Homozygosis for the benign variant c.388A>G (N130D, rs2306283) in 
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SLCO1B1 gene was present in patients who did not have AST elevated, while just one allele 
of this variant could protect from liver fibrosis. 
 
Table 22. SNPs with a potential protective effect by contingency tables 
Gene DNA/Protein dbSNP Variable tested Pearson’s Chi-square 
ABCB11 c.270T>C/p.F90= rs4148777 High BMI p = 0.043 
ABCB11 c.957A>G/p.G319= rs7563233 High GGT p = 0.041 
NOTCH2 c.7341T>A/p.G2447= rs6685892 High BMI p = 0.024 
SLCO1B1 c.388A>G/p.N130D rs2306283 
High AST p = 0.047 
High Fibroscan p = 0.044 
TJP2 c.1230A>G/p.L410= rs17062695 High ALT p = 0.001 
     
 
 
Table 23 shows SNPs that could act as potential risk factors.  
High ALT levels are associated with patients having at least one mutated C allele of the 
c.571T>C in SLCO1B1 (rs4149057): in fact, hetero and homozygous patients for this variant 
were doubly represented in ALT > 35 U/l category. The TJP2 variant Q159K (rs41305539) 
was also associated to high ALT. The presence of at least one allele of the IVS32 variant of 
the MYO5B gene c.4315+5G>C (rs488890) was associated to high GGT levels with a p = 0.025. 
The M1688V variant (rs112417235), still in MYO5B gene, was associated to high AP levels (p 
= 0.034). Homozygosis for the c.1197A>G (rs2301629) of the SLC25A13 gene and the presence 
of one allele of the c.2808C>T (rs2282336) and c.2820G>A (rs2282336) in TJP2 are also 
associated to high AP levels with p = 0.004 and p = 0.028 (for both in TJP2) respectively. The 
c.2808C>T and c.2820G>A appear always together in patients. One allele of the c.1249G>A, 
p.V417I in ABCC2 (rs2273697), c.1230A>G (rs17062695) and c.2820G>A in TJP2 are 
associated to a high BMI. F3 and F4 fibrosis stages are significantly associated to the 
presence of one allele of c.1230A>G in TJP2 and homozygous c.411G>A variants 





Table 23. SNPs with a potential risk factor by contingency tables 
Gene DNA/Protein dbSNP Tested variable  Pearson’s Chi-square 
SLCO1B1 c.571T>C/p.L191= rs4149057 High ALT p = 0.017 
TJP2 c.475C>A/p.Q159K rs41305539 High ALT p = 0.022 
MYO5B c.4315+5G>C rs488890 High GGT p = 0.025 
MYO5B c.5062A>G/p.M1688V rs112417235 High AP p = 0.034 
SLC25A13 c.1197A>G/p.L399= rs2301629 High AP p = 0.004 
TJP2 c.2808C>T/p.T936= rs2282336 High AP p = 0.028 
TJP2 c.2820G>A/p.A940= rs2095876 
High AP p = 0.028 
High BMI p = 0.017 
ABCC2 c.1249G>A/p.V417I rs2273697 High BMI p = 0.034 
TJP2 c.1230A>G/p.L410= rs17062695 
High BMI p = 0.013 
High Fibroscan p = 0.003 
SLCO1B1 c.411G>A/p.S137= rs11045818 High Fibroscan p = 0.043 
     
 
Due to the absence of normality of the distribution for several continuous parameters 
checked by the Kolmogorov-Smirnov test, non-parametric test was used accordingly to 
assess differences between genotypes: independent samples Mann-Whitney U test for 
testing differences with the mutated allele and Kruskal-Wallis one-way ANOVA test for 
analysing genotypes when wild-type, heterozygotes and homozygotes were comparable. 
Statistically significant SNPs associated to continuous parameters are reported below. SNPs 
with a potential protective effect are shown in table 24. 
 
Table 24. SNPs with a potential protective effect by Nonparametric Tests 
Gene DNA/Protein dbSNP Association p value Previously  
ABCB11 c.270T>C/p.Phe90= rs4148777 ≤BMI 0.036 * 
SLCO1B3 
c.699G>A/M233I rs7311358 ≤BMI 0.010  
c.1557A>G/p.A519=  rs2053098 ≤BMI 0.014  
ABCB4 c.1954A>G/p.R652G rs2230028 ≤tot. Bil. 0.047  
MYO5B 
c.4315+5G>C rs488890 ≤tot. Bil. 0.033  
c.4315+5G>C rs488890 ≤dir. Bil. 0.008  
ABCC2 c.1249G>A/p.V417I rs2273697 ≤Albumin 0.037  
TJP2 
c.2097G>A/p.M699I rs34774441 ≤Albumin 0.014  




Table 24 continued. SNPs with a potential protective effect by Nonparametric Tests.  
Gene DNA/Protein dbSNP Association p value Previously  
ABCC2 
c.4290G>T/p.V1430= rs1137968 ≤GGT 0.013  
c.4488C>T/p.H1496= rs8187707 ≤GGT 0.019  
TJP2 c.1230A>G/p.L410= rs17062695 ≤GGT 0.028  
* Previously associated by contingency tables’ Chi-square 
 
 
Two SNPs, c.270T>C (p.Phe90=) in ABCB11 and c.1230A>G (p.L410=) in TJP2 were 
previously tested for the same category by contingency tables (see above) and were 
confirmed by the latter analysis as associated to a low BMI and low ALT levels, respectively. 
Among potential protective SNPs, the C allele of the c.4315+5G>C in MYO5B gene (rs488890) 
was found to act as a protective factor for both direct and total bilirubin levels, showing a 
trend from wild-type, hetero and homozygous population in the whisker plots below. 
 
 
MYO5B c.4315+5G>C IVS32 rs488890 
 
                                                  0 = GG (n=21)                 1 = GC (n=19)                 2 = CC (n=14) 
 
  
p = 0.008 
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MYO5B c.4315+5G>C IVS32 rs488890 
 
                                                   0 = GG (n=20)                 1 = GC (n=21)                 2 = CC (n=15) 
 
SNPs with a potential risk factor are shown in table 25. 
 
Table 25. SNPs with a potential risk by Nonparametric Tests 
Gene DNA/Protein dbSNP Association p value Previously 
ABCC2 c.1249G>A/p.V417I rs2273697 >BMI 0.002 * 
NOTCH2 c.3625T>G/p.F1209V rs147223770 >BMI 0.046  
VPS33B c.151C>A/p.R51=  rs11542638 >BMI 0.033  
SLCO1B3 c.1557A>G/p.A519=  rs2053098 >ALT 0.018  
SLCO1B3 c.1833G>A/p.G611=  rs3764006 >ALT 0.018  
TJP2 c.1230A>G/p.L410= rs17062695 > Fibroscan 0.025 * 
TJP2 c.2808C>T/T936= rs2282336 >AP 0.003 * 
TJP2 c.2820G>A/p.A940= rs2095876 >AP 0.003 * 
* Previously associated by contingency tables’ Chi-square 
 
 
Among those SNPs, rs2273697 in ABCC2 and rs17062695, rs2282336 and rs2095876 in TJP2 
were previously tested for the same category by contingency tables (see above) and were 
confirmed by nonparametric test as associated to high BMI, high fibrosis (F3/F4) and high 
AP levels, respectively, as shown in the whisker plots below. The rs2282336 and rs2095876 
have the same p (0.003) at the Kruskal-Wallis ANOVA analysis because they are always both 
mutated in patients (rs2095876 not shown). 
p = 0.033 
103 
 
ABCC2 c.1249G>A p.V417I rs2273697 
 
                                                         0 = T allele (n=36)                               1 = C allele (n=18) 
 
 
TJP2 c.1230A>G p.Leu410= rs17062695 
 




p = 0.002 
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TJP2 c.2808C>T p.T936= rs2282336 
 
                                    0 = C allele (n=40)                              1 = T allele (n=15)                
 
 
Six patients have P/LP mutations, 30/80 (37,5 %) patients have at least one VUS, but all 
patients have several SNPs, ranging from one patient having 7 SNPs to another one having 





                                            Variants 
 





























The graph shows a Gaussian distribution. Interestingly, the patient carrying 37 SNPs had 
also the highest Fibroscan score in the population studied. The ANOVA analysis between 
the variant’s number per patient and Fibroscan scores revealed a significant p = 0.000. The 
more variants are present, the more probability to have high liver fibrosis.  
 
3.4.1 Case-control studies  
Case-control studies were performed by the de Finetti analysis. 
This analysis is part of the tests for deviation from Hardy-Weinberg equilibrium and tests 
for association. Several genotypes resulted in an increase or diminished risk for developing 
the disease, as shown in table 26. 
 
Table 26. SNPs resulted from de Finetti analysis 
Gene DNA/Protein dbSNP p value OR notes 
ABCB11 c.3084A>G/p.A1028A rs497692 0.01993 1.603 G allele risk 
JAG1 c.588C>T/p.C196=  rs1801138 0. 01293 2.808 T allele risk 
JAG1 c.765C>T/p.Y255=  rs1131695 0.00698 1.696 T allele risk 
SLCO1B3 c.699G>A/p.M233I rs7311358 0.00371 3.340 AA genotype risk 
SLCO1B3 c.767G>C/p.G256A rs60140950 0.02877 5.053 CC genotype risk 
ABCC2 c.3972C>T/p.I1324= rs3740066 0.01960 0.698 T allele protection 
CLDN1 c.369T>C/p.G123=  rs9869263 0.00356 0.464 C allele protection 
SLCO1B3 c.334T>G/p.S112A= rs4149117 0.00326 0.698 G allele protection 
VPS33B c.1540G>A/p.G514S rs11073964 0.00001 0.383 A allele protection 
OR: Odds Ratio, from 0 to 1 potential protection from the disease, over 1 potential risk for the disease. 
 
 
In ABCB11, the c.3084A>G, rs497692, showed a p = 0.01993 and a common Odds ratio (OR) 
of 1.603, indicating a slightly increased risk for the presence of the G allele. 
In JAG1, the c.588C>T, rs1801138 represents a risk factor for patients who carry the T allele 
(Odds ratio = 2.808 with a p = 0. 01293); another SNP, the c.765C>T, rs1131695, cause a 
potential risk factor for the T allele with an Odds ratio of 1.696 with a p = 0.00698. 
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In ABCC2, the c.3972C>T, rs3740066 showed a protective effect for the presence of the G 
allele (OR = 0.698). 
In CLDN1, the c.369T>C, rs9869263, resulted in a protective effect. In fact, patients carrying 
the C allele have a halved risk to develop the disease (Odds ratio = 0.464 with a p = 0. 00356). 
In VPS33B gene, with an Odds ratio = 0.383 and a p = 0.00001, the A allele resulted slightly 
protective in the c.1540G>A (p.G514S), rs11073964. 
In the SLCO1B3 gene, three SNPs have significant deviation from Hardy-Weinberg 
equilibrium and an association with the disease: the c.334T>G, rs4149117 had a slight 
protective effect for the presence of the G allele (Odds ratio = 0.698, p = 0.00326); the 
c.699G>A, rs7311358 is a risk factor for population carrying the AA genotype with a p = 
0.00371 and an OR = 3.340; in the SNP c.767G>C (p.G256A) rs60140950, only homozygosis 
(CC genotype) resulted in a very increased risk (OR = 5.053, p = 0.02877). 
 
3.5 Conclusions 
PFIC are usually considered pediatric diseases related to liver failure. Mutations in ATP8B1, 
ABCB11, ABCB4 and TJP2 have been associated to several cholestatic disorders. 
Hepatocellular carcinoma and cholangiocarcinoma to ABCB11 and TJP2, ICP is linked to 
ATP8B1, ABCB11 and ABCB4, LPAC to ABCB4, DIC to ABCB11 and ABCB4 and BRIC to 
ATP8B1 and ABCB11. Those mutations, genes and phenotypes are related and may coexist 
in the same patient. Furthermore, all four genes may be responsible for progressive forms 
of cholestasis or some benign forms could evolve to them. 
Of interest, we found a mean age of 36 years in subjects with disease-causing variants to 
confirm that P/LP mutations are not present only in children. Few studies linked mutations 
in PFIC genes with non-progressive diseases, especially in heterozygous subjects. In our 
cohort of patients with at least one disease-causing mutation, only four patients were 
homozygous or compound heterozygous for disease-causing variants in the same gene. 
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Colombo et al. 2011, described pathogenic mutations in ABCB4 in about a quarter of 
asymptomatic children where cholestatic disease was incidentally discovered via liver 
enzyme abnormalities and, not surprisingly, some of these patients carried a single 
heterozygous mutation. Gordo-Gilart et al. 2016, reported similar results in another cohort 
of pediatric patients in whom defects in a single allele of ABCB4 were identified in 9/67 
subjects. Some authors suggested that cryptogenic cholestasis in adults should be added to 
the spectrum of conditions associated with ABCB4 mutations. 
In our cohort, 12% of patients had at least one P/LP mutation and 20% of them presented a 
liver disorder in adulthood, suggesting once again that variants in PFIC genes are not 
exclusive to cholestatic diseases in childhood, but can also start with benign forms and lead 
to progressive forms and ESLD after years. 
Patients with P/LP mutations had higher Fibroscan scores, higher liver stiffness and a more 
aggressive phenotypes, but no significant correlation was observed.  
Many patients had multiple variants in the four classic PFIC genes. The same trend has been 
observed with the fifteen-gene panel. Patients in our cohort ranging from 7 to 35 variants 
and we demonstrate that also some SNPs can be significantly involved in biochemical 
parameters (such as high AST, ALT and GGT levels) and in phenotypic features (high liver 
fibrosis and tendency to have higher weights) that could accelerate the progression to liver 
failure. It is thus believable to hypothesize a synergistic haplotype effect in determining 
different cholestasis phenotypes and overlapping features, or specific interactions with 
environmental factors, in particular certain drugs. A reduction of bile flow represents a 
pathophysiological state and can be critical for metabolism of many drugs. This is supported 
by MDR3 and BSEP deficiencies being known to be associated to different levels of DIC. 
Examples are SNPs V444A and M677V in ABCB11 and I237= in ABCB4. We found V444A in 
83.3% of patients (38% in homozygous state): this benign variant was reported with AF in 
the general population of 56.9 and of 65.9% in cholestatic patients with no BSEP disease-




All the fifteen genes had at least one SNP more frequent in our cohort than in TSI population 
from 1000 Genome. Some of them had a great deviation from HW equilibrium and a 
statistically significant association with the disease. Among genes with a high number of 
SNP in relation to their total variants’ number we found CLDN1, SLCA25A13, SLCO1B1 and 
SLCO1B3. These genes are all involved in cell adhesion and organic anion transport and it 
is possible that the simultaneous presence of more variants at the same time could also 
changes the normal activity of this protein chain.   
TJP2 resulted the most affected gene with 25 variants identified. ABCB11, MYO5B and 
ABCB4 also had a high number of variants (22 the first two genes and 20 the latter) but only 
ABCB11 and ABCB4 had also different P/LP mutations. The ATP8B1 gene had the higher 
VUS rate and the lowest rate of SNPs. 
We did not find mutations or SNPs in the recently PFIC5 associated gene NR1H4: we found 
just one VUS. One explanation could be that this gene is involved mainly in pediatric or 
childhood phenotypes, while here we have a young-adult and adult population cohort. 
After all, our detection rate is comparable to the literature and to other studies proposing 
multi-gene panels. Some research groups are able to facilitate genetic diagnosis in children 
with overt intrahepatic cholestasis phenotypes, but it remains elusive in adult populations. 
The failure to find pathogenic mutations in the major part of our cohort may be explained 
by the following, not mutually exclusive, reasons. First, the deep intronic regions, promoters 
and untranslated regions (5’-3’UTR) of all genes have never been analysed by NGS-method. 
Apart for MLPA analysis of the ABCB4 gene, large genomic deletions of the other eleven 
genes have not been analysed. In fact, NGS sequencing does not allow to detect those 
genomic rearrangements. Second, coding variants currently classified as non-pathogenic, 
including silent mutations and some missense mutations, may be of pathogenic relevance 
through modulation of mRNA splicing and/or stability; this possibility has not been 
systematically tested to date. Third, some “PFIC” cases may have been wrongly clinically 
diagnosed. Finally, the high proportion of unsolved cases suggests novel genetic etiologies 
that remain to be elucidated. With this purpose, exome analysis on some interesting families 
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could highlight new mutations on other genes potentially involved in biliary synthesis, 
transport and reuptake.  
The NGS-based developed protocols turned out to be both faster and cost-saving compared 
to the traditional Sanger sequencing, allowing us to obtain rapid medical reports for PFIC 
patients in just few weeks. 
Analysing reagent costs and their respective labour time to reach a complete molecular 
diagnosis between the conventional Sanger sequencing usually adopted in many public 
hospital laboratories and the NGS method, we can assess that the last one is absolutely more 
efficient, time and cost saving. Moreover, NGS technique resulted very suitable for our 
purpose of sequencing a multi-gene panel.   
Patients can be genotyped with NGS protocols at reagent costs per patient five-times less 
than Sanger sequencing method. Regarding the benchwork, the hands-on time is required 
just for preparing libraries. With the introduction of Ion Chef System in our workflow, in 
fact, all the other steps are automatized. The subsequent data analysis is considerably faster 
and can be completed in just few hours. 
In conclusion, the NGS-based genetic analysis for PFIC disease is a highly accurate and 
reliable approach for mutation analysis achieving high sensitivity with a faster turnaround 
time and lower cost. 
NGS would be an appropriate new gold-standard for clinical genetic testing of Progressive 






1. Boyer JL. Bile formation and secretion. Compr Physiol 2013:3: 1035-78. 
2. Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol 
Med 2003: 9: 558-64. 
3. Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and 
regulation. Physiol Rev 2003:83:633-71. 
4. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 
2015: 56: 1085-99. 
5. Hegade VS, Speight RA, Etherington RE, Jones DE. Novel bile acid therapeutics for 
the treatment of chronic liver diseases. Therap Adv Gastroenterol 2016: 9: 376-91. 
6. Samant, H., Manatsathit, W., Dies, D., Shokouh-Amiri, H., Zibari, G., Boktor, M., & 
Alexander, J. S. Cholestatic liver diseases: An era of emerging therapies. World Journal 
of Clinical Cases, 2019. 7(13), 1571–1581. 
7. Jansen PL, Ghallab A, Vartak N, et al. The ascending pathophysiology of cholestatic 
liver disease. Hepatology 2017:65: 722-38. 
8. Wagner M, Zollner G, Trauner M. Nuclear receptor regulation of the adaptive 
response of bile acid transporters in cholestasis. Semin Liver Dis 2010: 30: 160-77. 
9. Matsubara T, Li F, Gonzalez FJ. FXR signaling in the enterohepatic system. Mol Cell 
Endocrinol 2013: 368: 17-29. 
10. Cai SY, Ouyang X, Chen Y, Soroka CJ, Wang J, Mennone A, Wang Y, et al. Bile acids 
initiate cholestatic liver injury by triggering a hepatocyte-specific inflammatory 
response. JCI Insight 2017: 2: e90780. 
11. Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med 
1998; 339: 1217-1227. 
12. Hori T, Nguyen JH, Uemoto S. Progressive familial intrahepatic cholestasis. 
Hepatobiliary Pancreat Dis Int. 2010; 9:570–8. 
111 
 
13. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. The spectrum of liver diseases 
related to ABCB4 gene mutations: pathophysiology and clinical aspects. Semin Liver 
Dis 2010; 30:134–46. 
14. Clayton RJ, Iber FL, Ruebner BH, McKusick VA. Byler disease. Fatal familial 
intrahepatic cholestasis in Amish kindred. Am J Dis Child 1969; 117:112–24. 
15. Srivastava A. Progressive familial intrahepatic cholestasis. J Clin Exp Hepatol. 2014; 
4(1):25–36. 
16. Strautnieks SS, Kagalwalla AF, Tanner MS, Knisely AS, Bull L, Freimer N, et al. 
Identification of a locus for progressive familial intrahepatic cholestasis PFIC2 on 
chromosome 2q24. Am J Hum Genet 1997; 61:630–633. 
17. Jacquemin E, De Vree JM, Cresteil D, Sokal EM, Sturm E, Dumont M, et al. The wide 
spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis 
of adulthood. Gastroenterology 2001;120:1448–1458. 
18. Pauli-Magnus C, Lang T, Meier Y, Zodan-Marin T, Jung D, Breymann C, et al. 
Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-
glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of 
pregnancy. Pharmacogenetics 2004;14:91–102 
19. Sambrotta M, Strautnieks S, Papouli E, Rushton P, Clark BE, Parry DA, Logan CV, 
Newbury LJ, Kamath BM, Ling S, Grammatikopoulos T, Wagner BE, Magee JC, Sokol 
RJ, Mieli-Vergani G; University of Washington Center for Mendelian Genomics, 
Smith JD, Johnson CA, McClean P, Simpson MA, Knisely AS, Bull LN, Thompson RJ. 
Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014 
Apr;46(4):326-8. 
20. Gomez-Ospina N, Potter CJ, Xiao R, Manickam K, Kim M-S, Kim KH. Mutations in 
the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. 
Nat Commun. 2016; 7:10713. 
21. Qiu YL, Gong JY, Feng JY, Wang RX, Han J, Liu T, Lu Y, Li LT, Zhang MH, Sheps JA, 
Wang NL, Yan YY, Li JQ, Chen L, Borchers CH, Sipos B, Knisely AS, Ling V, Xing 
QH, Wang JS. Defects in myosin VB are associated with a spectrum of previously 
112 
 
undiagnosed low γ-glutamyltransferase cholestasis. Hepatology 2017 May;65(5):1655-
1669. 
22. Bull LN, van Eijk MJ, Pawlikowska L, DeYoung JA, Juijn JA, Liao M, Klomp LW, 
Lomri N, Berger R, Scharschmidt BF, Knisely AS, Houwen RH, Freimer NB. A gene 
encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nature 
Genetics vol. 18, no. 3, pp. 219–224, 1998. 
23. S.W. C. VanMil, L.W. J. Klomp, L. N. Bull, andR.H. J. Houwen. FIC1 disease: A 
spectrum of intrahepatic cholestatic disorders. Seminars in Liver Disease vol. 21, no. 4, 
pp. 535–544, 2001. 
24. A. Miyahawa-Hayashino, H. Egawa, T. Yorifuji, M. Hasegawa, H. Haga, T. 
Tsuruyama, M. C. Wen, R. Sumazaki, T. Manabe, S. Uemoto. Allograft steatohepatitis 
in progressive familial intrahepatic cholestasis type 1 after living donor liver 
transplantation. Liver Transplantation vol. 15, no. 6, pp. 610–618, 2009. 
25. Nicastro E, Stephenne X, Smets F, Fusaro F, de Magnee C, Reding R, Sokal E. M. 
Recovery of graft steatosis and protein-losing enteropathy after biliary diversion in a 
PFIC 1 liver transplanted child. Pediatr Transplant. 2012;16(5):E177–82. 
26. Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, 
Bernard O. Ursodeoxycholic acid therapy in pediatric patients with progressive 
familial intrahepatic cholestasis. Hepatology. 1997. 
27. Davis AR, Rosenthal P, Newman TB. Nontransplant surgical interventions in 
progressive familial intrahepatic cholestasis. J Pediatr Surg. 2009;44:821–7. 
28. Lykavieris P, van Mil S, Cresteil D. Progressive familial intrahepatic cholestasis type 
1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhoea, 
and appearance of liver steatosis after liver transplantation. J Hepatol. 2003;39:447–52. 
29. Kubitz R, Dröge C, Stindt J, Weissenberger K, Häussinger D. The bile salt export 
pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012; 36:536–53. 
30. Ananthanarayanan M, Li Y, Surapureddi S, Balasubramaniyan N, Ahn J, Goldstein 
JA, et al. Histone H3K4 trimethylation by MLL3 as part of ASCOM complex is critical 
113 
 
for NR activation of bile acid transporter genes and is downregulated in cholestasis. 
Am J Physiol Gastrointest Liver Physiol 2011;300:G771—81 
31. Woods A, Heslegrave AJ, Muckett PJ, Levene AP, Clements M, Mobberley M, Ryder 
TA, Abu-Hayyeh S, Williamson C, Goldin RD, Ashworth A, Withers DJ, Carling D. 
LKB1 is required for hepatic bile acid transport and canalicular membrane integrity 
in mice. Biochem J. 2011; 434:49—60. 
32. Scheimann AO, Strautnieks SS, Knisely AS, Byrne JA, Thompson RJ, Finegold MJ. 
Mutations in Bile Salt Export Pump (ABCB11) in Two Children with Progressive 
Familial Intrahepatic Cholestasis and Cholangiocarcinoma. Journal of Pediatrics. vol. 
150, no. 5, pp. 556–559, 2007. 
33. Sticova E, Jirsa M, Pawlowska J. New Insights in Genetic Cholestasis: From Molecular 
Mechanisms to Clinical Implications. Canadian Journal of Gastroenterology and 
Hepatology. 2018. doi.org/10.1155/2018/2313675 
34. Gonzales E, Grosse B, Schuller B, Davit‐Spraul A, Conti F, Guettier C, Cassio D, 
Jacquemin E. Targeted pharmacotherapy in progressive familial intrahepatic 
cholestasis type 2: Evidence for improvement of cholestasis with 4‐phenylbutyrate. 
Hepatology 2015. doi.org/10.1002/hep.27767. 
35. Kubitz R, Dröge C, Kluge S, Stross C, Walter N, Keitel V, Häussinger D, Stindt J. 
Autoimmune BSEP disease: disease recurrence after liver transplantation for 
progressive familial intrahepatic cholestasis. Clin Rev Allergy Immunol. 2015 Jun;48(2-
3):273-84. doi: 10.1007/s12016-014-8457-4. 
36. de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, 
Desrochers M, Burdelski M, Bernard O, Oude Elferink RP, Hadchouel M. Mutations 
in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad 
Sci U S A. 1998 Jan 6;95(1):282-7. DOI: 10.1073/pnas.95.1.282. 
37. Groen A., Romero M.R., Kunne C., Hoosdally S.J., Dixon P.H., Wooding C., 
Williamson C., Seppen J., Van den Oever K., Mok K.S., Paulusma C.C., Linton K.J., 
Oude Elferink R.P. Complementary functions of the flippase ATP8B1 and the 
114 
 
floppase ABCB4 in maintaining canalicular membrane integrity. Gastroenterology 
141:1927-1937(2011). 
38. Morita S.Y., Tsuda T., Horikami M., Teraoka R., Kitagawa S., Terada T. Bile salt-
stimulated phospholipid efflux mediated by ABCB4 localized in nonraft membranes. 
J. Lipid Res. 2013 May;54(5):1221-30. doi: 10.1194/jlr.M032425. 
39. Wendum D. Barbu V. Rosmorduc O. Arriv´e L. Fl´ejou J.-F, and Poupon R. Aspects 
of liver pathology in adult patients with MDR3/ABCB4 gene mutations. Virchows 
Archiv, 2012, vol. 460, no. 3, pp. 291–298. 
40. Morotti RA, Suchy FJ, Magid MS. Progressive familial intrahepatic cholestasis (PFIC) 
type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis. 2011 
Feb;31(1):3-10. 
41. Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino 
G, Russo G, Castellani D, Willson TM, Pruzanski M, Pellicciari R, Morelli A. 
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in 
estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005; 313:604–12. 
42. Sambrotta M. and Thompson R. J. Mutations in TJP2, encoding zona occludens 2, and 
liver disease. Tissue Barriers, 2015 vol. 3, no. 3, Article ID e1026537. 
43. Holczbauer Á, Gyöngyösi B, Lotz G, Szijártó A, Kupcsulik P, Schaff Z, Kiss A. 
Distinct claudin expression profiles of hepatocellular carcinoma and metastatic 
colorectal and pancreatic carcinomas. J Histochem Cytochem. 2013 Apr; 61(4):294-305. 
44. Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S. Direct binding of three 
tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini 
of claudins. J Cell Biol. 1999 Dec 13; 147(6):1351-63. 
45. Zhou, S., Hertel, P. M., Finegold, M. J., Wang, L., Kerkar, N., Wang, J., Wong, L.-J. C., 
Plon, S. E., Sambrotta, M., Foskett, P., Niu, Z., Thompson, R. J., Knisely, A. S. 
Hepatocellular carcinoma associated with tight-junction protein 2 deficiency. 
Hepatology. 62: 1914-1916, 2015. 
46. Carlton VE, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss 
KA, Shneider BL, Lim WA, Salen G, Morton DH, Bull LN. Complex inheritance of 
115 
 
familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat Genet. 
2003 May;34(1):91-6. DOI: 10.1038/ng1147. 
47. Chen HL, Li HY, Wu JF, Wu SH, Chen HL, Yang YH, Hsu YH, Liou BY, Chang MH, 
Ni YH. Panel-Based Next-Generation Sequencing for the Diagnosis of Cholestatic 
Genetic Liver Diseases: Clinical Utility and Challenges. J Pediatr 2019; 205: 153-159.e6 
DOI: 10.1016/j.jpeds.2018.09.028. 
48. Koutsounas I, Theocharis S, Delladetsima I, Patsouris E, and Giaginis C. Farnesoid x 
receptor in human metabolism and disease: the interplay between gene 
polymorphisms, clinical phenotypes and disease susceptibility. Expert Opinion on 
Drug Metabolism & Toxicology, 2015, vol. 11, no. 4, pp. 523–532. 
49. Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J 
Hepatol. 2015;63:1023–37. 
50. Bull LN, Thompson RJ. Progressive Familial Intrahepatic Cholestasis. Clin Liver Dis 
2018. 22: 657–669. 
51. Müller T, Hess MW, Schiefermeier N, Pfaller K, Ebner HL, Heinz-Erian P, Ponstingl 
H, Partsch J, Röllinghoff B, Köhler H, Berger T, Lenhartz H, Schlenck B, Houwen RJ, 
Taylor CJ, Zoller H, Lechner S, Goulet O, Utermann G, Ruemmele FM, Huber LA, 
Janecke AR. MYO5B mutations cause microvillus inclusion disease and disrupt 
epithelial cell polarity. Nat Genet. 2008 Oct;40(10):1163-5. doi: 10.1038/ng.225. 
52. Siahanidou T, Koutsounaki E, Skiathitou A, Stefanaki K, Marinos E, Panajiotou I, 
Chouliaras G. Extraintestinal manifestations in an infant with microvillus inclusion 
disease: complications or features of the disease? Eur J Pediatr. 2013;172:1271-1275. 
53. Girard M, Lacaille F, Verkarre V, Mategot R, Feldmann G, Grodet A, Sauvat F, Irtan 
S, Davit-Spraul A, Jacquemin E, Ruemmele F, Rainteau D, Goulet O, Colomb V, 
Chardot C, Henrion-Caude A, Debray D. MYO5B and bile salt export pump 
contribute to cholestatic liver disorder in microvillous inclusion disease. Hepatology 
2014; 60:301-310. 
54. Gonzales E, Taylor SA, Davit-Spraul A, Thébaut A, Thomassin N, Guettier C, 
Whitington FP, Jacquemin E. MYO5B mutations cause cholestasis with normal serum 
116 
 
gamma-glutamyl transferase activity in children without microvillous inclusion 
disease. Hepatology 2017; 65:164–73. 
55. Van Mil S.W. C., Houwen R. H. J., and Klomp L.W. J. Genetics of familial 
intrahepatic cholestasis syndromes. Journal of Medical Genetics, 2005. vol. 42, no. 6, 
pp. 449–463. 
56. Dröge C. Bonus M. Baumann U. Klindt C. Lainka E. Kathemann S. Brinkert F. 
Grabhorn E. Pfister ED. Wenning D. Fichtner A. Gotthardt DN. Weiss KH. 
McKiernan P. Puri RD. Verma IC. Kluge S. Gohlke H. Schmitt L. Kubitz R. 
Häussinger D. Keitel V. Sequencing of FIC1, BSEP and MDR3 in a large cohort of 
patients with cholestasis revealed a high number of different genetic variants. J 
Hepatol. 2017 Dec;67(6):1253-1264. 
57. Brenard R, Geubel AP, Benhamou JP. Benign recurrent intrahepatic cholestasis. J Clin 
Gastroenterol. 1989;11:546–51. 
58. Vitale G, Gitto S, Vukotic R, Raimondi F, Andreone P. Familial intrahepatic 
cholestasis: New and wide perspectives. Dig Liver Dis. 2019 Jul;51(7):922-933. 
59. Van Ooteghem NA, Klomp LW, van Berge-Henegouwen GP, Houwen RH. Benign 
recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic 
cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol. 2002 Mar;36(3):439-
43.  
60. Folvik G, Hilde O, Helge GO. Benign recurrent intrahepatic cholestasis: review and 
long-term follow-up of five cases. Scand J Gastroenterol. 2012; 47:482–8. 
61. Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic 
cholestasis: From UDCA to FXR, PXR and beyond. Journal of Hepatology, vol. 62, no. 
1, pp. S25–S37, 2015. 
62. Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van 
Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH. 
Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic 
cholestasis. Hepatology 2006; 43:51–3. 
117 
 
63. Ovadia C, Seed PT, Sklavounos A, Geenes V, Di Ilio C, Chambers J, Kohari K, Bacq 
Y, Bozkurt N, Brun-Furrer R, Bull L, Estiú MC, Grymowicz M, Gunaydin B, Hague 
WM, Haslinger C, Hu Y, Kawakita T, Williamson C. Association of adverse perinatal 
outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results 
of aggregate and individual patient data meta-analyses. The Lancet 2019;393:899–909. 
64. Jin WY, Lin SL, Hou RL, Chen XY, Han T, Jin Y, Tang L, Zhu ZW, Zhao ZY. 
Associations between maternal lipid profile and pregnancy complications and 
perinatal outcomes: a population-based study from China. BMC Pregnancy Childbirth. 
2016 Mar 21;16:60. 
65. Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol. 2014; 
124:120–33. 
66. Van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf 
SF,Houwen RH. Familial cholestasis: progressive familial intrahepatic cholestasis, 
benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. 
Best Pract Res Clin Gastroenterol. 2010; 24:541–53. 
67. Pauli-Magnus C, Meier PJ, Stieger B. Genetic Determinants of Drug-induced 
Cholestasis and Intrahepatic Cholestasis of Pregnancy. Semin Liver Dis 2010;30:147–
159. 
68. Painter JN, Savander M, Ropponen A, Nupponen N, Riikonen S, Ylikorkala O, 
Lehesjoki AE, Aittomäki K. Sequence variation in the ATP8B1 gene and intrahepatic 
cholestasis of pregnancy. European Journal of Human Genetics (2005) 13, 435–439. 
69. Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk 
V, Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White 
R, Williamson C. Functional variants of the central bile acid sensor FXR identified in 
intrahepatic cholestasis of pregnancy. Gastroenterology 2007;133:507–16. 
70. Dixon PH, Sambrotta M, Chambers J, Taylor-Harris P, Syngelaki A, Nicolaides K, 
Knisely AS, Thompson RJ, Williamson C. An expanded role for heterozygous 
mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis 
of pregnancy. Sci Rep 2017; 7:11823. 
118 
 
71. Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 
2016; 64:933–45. 
72. Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomäki K. Intrahepatic cholestasis 
of pregnancy as an indicator of liver and biliary diseases: a population-based study. 
Hepatology 2006;43:723–8. 
73. Shapiro MA, Lewis JH. Causality assessment of drug induced hepatotoxicity: 
promises and pitfalls. Clin Liver Dis. 2007;11(3):477–505. 
74. Padda MS, Sanchez M, Akhtar AJ, Boyer JL. Drug-induced cholestasis. Hepatology 
2011;53:1377–87. 
75. Rosmorduc O, Hermelin B, Poupon R. MDR3 gene defect in adults with symptomatic 
intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 2001; 
120:1459- 67. 
76. Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association 
with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2007; 11(2):29. 
77. Erlinger S. Low phospholipid-associated cholestasis and cholelithiasis. Clin Res 
Hepatol Gastroenterol. 2012; 36(Suppl. 1):S36–40. 
78. Poupon R, Rosmorduc O, Boëlle PY, Chrétien Y, Corpechot C, Chazouillères O, 
Housset C, Barbu V. Genotype-phenotype relationships in the low-phospholipid-
associated cholelithiasis syndrome: a study of 156 consecutive patients. Hepatology 
2013; 58:1105–10. 
79. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated 
with canalicular transport defects: current and future therapies. J Hepatol 2010; 52: 
258-271. 
80. Van der Woerd WL, Houwen RHJ, van de Graaf SFJ. Current and future therapies 
for inherited cholestatic liver diseases. World J Gastroenterol. 2017 Feb 7; 23(5): 763-
775. 
81. Stapelbroek JM, van Erpecum KJ, Klomp LW, Venneman NG, Schwartz TP, van 
Berge Henegouwen GP, Devlin J, van Nieuwkerk CM, Knisely AS, Houwen RH. 
119 
 
Nasobiliary drainage induces long lasting remission in benign recurrent intrahepatic 
cholestasis. Hepatology 2006; 43: 51-53. 
82. Whitington PF, Whitington GL. Partial external diversion of bile for the treatment of 
intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 1988; 95: 
130-136. 
83. Van der Woerd WL, Kokke FT, van der Zee DC, Houwen RH. Total biliary diversion 
as a treatment option for patients with progressive familial intrahepatic cholestasis 
and Alagille syndrome. J Pediatr Surg. 2015; 50: 1846-1849. 
84. Mali VP, Fukuda A, Shigeta T, Uchida H, Hirata Y, Rahayatri TH, Kanazawa H, 
Sasaki K, de Ville de Goyet J, Kasahara M. Total internal biliary diversion during liver 
transplantation for type 1 progressive familial intrahepatic cholestasis: a novel 
approach. Pediatr Transplant. 2016; 20: 981-986. 
85. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, 
Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. Vascularized and functional 
human liver from an iPSC-derived organ bud transplant. Nature 2013; 499: 481-484. 
86. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M, Sato T, Hamer K, 
Sasaki N, Finegold MJ, Haft A, Vries RG, Grompe M, Clevers H. In vitro expansion 
of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013; 494: 
247-250. 
87. Wang L, Wu J, Fang W, Liu GH, Izpisua Belmonte JC. Regenerative medicine: 
targeted genome editing in vivo. Cell Res 2015; 25: 271-272. 
88. Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic 
research to diagnostics. Clin Chem. 2009 Apr;55(4):641-58. 
89. Merriman B, Ion Torrent R&D Team, Rothberg JM. Progress in ion torrent 
semiconductor chip-based sequencing. Electrophoresis. 2012 Dec;33(23):3397-41. 
90. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, 
Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Standards and guidelines for 
the interpretation of sequence variants: a joint consensus recommendation of the 
120 
 
American College of Medical Genetics and Genomics and the Association for 
Molecular Pathology. Genet Med. 2015 May;17(5):405-24. 
91. Mendell NR, Simon GA. A general expression for the variance-covariance matrix of 
estimates of gene frequency: the effects of departures from Hardy-Weinberg 
equilibrium. Ann Hum Genet 1984, 48, 283-286 
92. Vitale G, Pirillo M, Mantovani V, Marasco E, Aquilano A, Gamal N, Francalanci P, 
Conti F, Andreone P. Bile salt export pump deficiency disease: two novel, late onset, 
ABCB11 mutations identified by next generation sequencing. Ann Hepatol. 2016 Sep 
- Oct;15(5):795-800. 
93. Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, Bordo D, 
Coviello DA. Molecular characterization and structural implications of 25 new 
ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur 
J Hum Genet. 2007 Dec;15(12):1230-8. 
94. Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, and 
Massouras A. VarSome: The Human Genomic Variant Search Engine. Oxford 
Bioinformatics, bty897, 30 October 2018. 
121 
 
 
